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“የጌታ?ፈቃድ?ይሁን?ብለን?ዝም?አልን”  
“we ceased, saying, The will of the Lord will be done”

ABSTRACT 
HBV vaccination prevents HBV infection and related liver cancer. Immunological 
dysfunctions of Tfh and B cells in HIV-1 infected individuals may affect the response to 
HBV vaccine. The general objective of this thesis was to elucidate HBV vaccine response in 
HIV-1 infected children receiving ART, to assess functional and phenotypic properties of 
pTfh cells in HBV vaccinated children and to study whether HBV vaccination may have a 
role in reducing the size of HIV-1 reservoirs. In paper I, we showed reduced frequencies of 
pTfh cells in HIV-1 infected children compared to healthy controls and of pTfh cells 
expressing the co-stimulatory molecules ICOS and PD1, important to mediate the interaction 
of Tfh cells with B cells. The frequency of IL-4 expressing pTfh cells and of resting memory 
B cells was also lower in infected children; on the contrary, an expansion of exhausted 
memory B cells was detected in this group. In paper II, all children who received HBV 
vaccination, except four, displayed a strong vaccine response at 1 month post-vaccination. 
Lower plasma levels of anti-HBs antibodies (Abs) were measured in HIV-1 infected children 
compared to controls at 1 month and 6 months post-vaccination. HIV-1 infected children had 
elevated plasma CXCL13 levels compared to controls at all time points; changes in plasma 
CXCL13 concentration were however not observed following vaccination. As the functional 
and phenotypic properties of pTfh cells were similar in both groups pre- and post-
vaccination, alterations in pTfh properties could not explain the reduced vaccine response in 
HIV-1 infected children. In a yet unpublished study, we showed an altered frequency of B 
cell subsets in HIV-1 infected children which correlated with anti-HBs Ab titers after 
vaccination. In paper III, the number of HIV-1 DNA copies in PBMCs was unchanged after 
vaccination with a combined HBV and HAV vaccine in HIV-1 infected children; however, 
54% of these individuals showed a decline in the size of HIV-1 DNA reservoir after 
vaccination. The change was most likely related to vaccination since the children were on 
ART for a median of 7.2 years and had therefore likely reached a plateau phase for HIV-1 
DNA decay after ART initiation. EM CD8+ T cells were the stronger predictors of the 
change in HIV-1 DNA copies using multivariate analysis. In conclusion, three doses of 
accelerated HBV vaccination induced high anti-HBs Abs in both HIV-1 infected and control 
children. A rapid decline of anti-HBs Abs in plasma after 6 months from vaccination suggests 
the need of an additional booster dose for HBV vaccine. The role of HBV vaccination in 
reducing HIV-1 DNA reservoirs should be investigated further. 
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1 CHAPTER I: INTRODUCTION  
1.1 BACKGROUND    
Infection with HIV-1 is a compelling public health problem and among the leading causes of 
death in sub-Saharan Africa. Globally, the virus infected more than 70 million people and killed 
about 35 million lives so far. Sub-Saharan Africa is disproportionately affected by HIV-1 
burden as infections in this part of the world accounted for two-third of HIV-1 infection 
worldwide. In 2017, around 20.9 million people living with HIV-1 (PLWH) were accessing 
antiretroviral therapy (ART) globally. In pregnant women living with HIV-1, ART prevents 
mother-to-child transmission (PMTCT) of the virus; 76% of HIV-1 infected mothers were 
accessing the treatment in 2016 [1, 2]. HIV-1 and Hepatitis B virus (HBV) have common 
modes of transmission and, in co-infected individuals, the clinical outcomes linked to these two 
infections are exacerbated [3]. HBV infection is vaccine preventable; vaccine specific 
antibodies, however, wane quickly in HIV-1 infected patients. Thus, both ART treated and 
untreated HIV-1 infected individuals, even if vaccinated, will be at risk of acquiring HBV 
infection and related complications [4-7]. Immune response to HBV vaccine improved in    
HIV-1 infected individuals by increasing the vaccine dosage, the frequency of boosters and the 
use of different types of adjuvants [8, 9].  
1.2 HIV-1 EPIDEMIOLOGY  
In 1981, five young homosexual men were treated for Pneumocystis carinii pneumonia in Los 
Angeles hospitals. These patients had a history of cytomegalovirus (CMV) and mucosal 
candida infections and they displayed a very poor response to mitogens and antigens [10]. 
Unusual forms of Kaposi’s sarcoma were also seen in young homosexual men who were 
positive for CMV antibodies and hepatitis B surface antigen (HBsAg) or hepatitis B surface 
antibody (anti-HBs) [11]. Patients were also experiencing severe deficiency in cellular immune 
responses and this syndrome was later on named acquired immunodeficiency syndrome (AIDS) 
[12]. The causative agent of AIDS was discovered through repeated isolations of the virus, 
initially named human T-cell lymphotropic virus type III (HTLV-III), from AIDS and pre-
AIDS patients; a serological test was developed soon thereafter for screening blood before 
transfusion [13-17]. In 1986 the virus was renamed to human immunodeficiency virus (HIV) by 
the International Committee of the Taxonomy of Viruses (ICTV) [18].  
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Retroviridae is a large family of viruses which relies on a ribonucleic acid (RNA)-dependent 
deoxyribonucleic acid (DNA) polymerase (reverse transcriptase) capable of synthesizing DNA 
from the virus RNA. Of the seven Retroviridae sub-families, delta-retroviruses comprise the T 
lymphotropic viruses HTLV-1 and HTLV-2 which cause T cell lymphoma and neurological 
disease, and the lentiviruses HIV-1 and HIV-2 which cause AIDS [19]. HIV-2 was isolated 
from West Africa patients in Guinea Bissau and Cape Verde [20]. Chimpanzees and/or gorilla 
are more likely to be the source of the initial HIV-1 transmission to humans; on the other hand, 
sooty mangabeys are likely the source of HIV-2 since a closely related group of viruses, called 
simian immunodeficiency viruses (SIVs), was isolated from primates in sub-Saharan Africa 
[21, 22].  
There are four distinct HIV-1 groups; M (major or main), N (non-M or non-O) [23], O (outlier) 
[24] and P [25, 26]. HIV-1 group M is responsible for the world-wide pandemic and is 
subdivided into 9 clades or subtypes (A to D, F to H, J and K) and CRFs (circulating 
recombinant forms) originated through the recombination of subtypes are also included in M 
[27]. Subtype C is the most dominant (48%) of all subtypes of HIV-1 M group and this subtype 
is present in India, Southern Africa, and Eastern Africa including Ethiopia. HIV-1 M subtypes 
A (12%) and B (11%) have a large distribution globally. Subtype B dominates in Western and 
Central Europe, Australia, North America, the Caribbean and Latin America. Subtype A is 
present in Western and Eastern Africa, Eastern Europe, Russia and Ukraine [28]. Subtype B 
(47%) was the dominant subtype in HIV-1 infected individuals in Sweden, followed by subtype 
C and CRFs; an increase in non-B subtypes over-time was due to immigration from Africa and 
Thailand [29]. In Ethiopia, the HIV-1 epidemic is predominantly due to the C-subtype, which 
can be subdivided into sub-cluster C and sub-cluster C' [30, 31]. HIV-2 is a less virulent virus 
with a lower transmission efficacy; only eight (A-H) groups were identified for HIV-2 [32]. 
Globally, the incidence of HIV-1 infection decreased from 2.1 million in 2015 to 1.8 million in 
2016; the decline in the incidence of HIV-1 infection was estimated to be 11% and 47% since 
2010 in adult and children, respectively [1, 33]. The prevalence of HIV-1 increased over the 
years but the death rate declined through an increased access to ART. A total of 19.5 million 
people, 54% of 34.5 million adults and 43% of 2.1 million children (Figure 1), were accessing 
ART in 2016 [1]. Global scale up in the provision and access to ART has led to the removal of 
HIV from the top 10 causes of death world-wide [34]. The estimated prevalence of HIV-1 in 
Western and central Europe, and North America was 2.1 million which contributed only to 
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5.7% of HIV-1 infection globally in 2016. The largest contribution (70%) to HIV-1 prevalence 
was from Sub-Saharan Africa with an estimated prevalence of 25.5 million infected, 54% of 
those individuals accessing ART and over 0.7 million deaths reported in 2016 [1]. In Sweden, 
eleven thousand people are estimated to live with HIV-1 and, among them, less than 100 were 
children. In 2016, ART coverage was 83% among the total number of people living with HIV-
1, and was greater than 95% among children [35]. In Ethiopia, the rate of HIV-1 prevalence in 
adults is estimated to be 1.1% and 710 thousand people estimated to live with HIV-1, of these 
62 thousand were children. The coverage of ART in Ethiopia was 59% in children and adults; 
however, children ART coverage was very low (35%). The ART coverage among HIV-1 
infected Ethiopian pregnant women for PMTCT was 69% with 4200 new HIV-1 infection 
estimated in 2016 [36]. 
 
Figure 1. Global epidemiology and access to antiretroviral treatment for HIV infected children 
in 2016 (Adapted from [37]). 
1.3 PATHOGENESIS OF HIV-1 INFECTION 
1.3.1 HIV-1 entry and replication   
Most of HIV-1 transmissions occur during heterosexual intercourses as the virus passes the 
mucosal barrier through microlesions in this compartment [19, 38]. Mother-to-child 
transmission (MTCT) is another route of HIV-1 transmission which may occur at pregnancy, 
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labour, delivery and breastfeeding. The rate of MTCT is 15 to 45% without any interventions 
but the transmission can be reduced below 5% through ART administration and other effective 
interventions during peripartum and postpartum periods [39].  
The complex life cycle of HIV-1 is initiated when the viral envelope (env) proteins bind to the 
virus receptor CD4 on host cells at the site of transmission [40]. The binding of the HIV-1 
external envelope glycoprotein (gp120) to the CD4+ receptor on the host T cells triggers a 
gp120 conformational change thus exposing part of the gp41 protein which will interact with 
CCR5 and/or CXCR4 co-receptors on CD4+ T cells [41, 42]. Non-syncytium inducting viruses 
preferentially use CCR5 (R5) as co-receptors in early phase of HIV-1 infection; syncytium 
inducing viruses which utilize CXCR4 (X4) as co-receptors can be found during the chronic 
phase in approximately 50% of infected patients [43, 44]. Upon entry into the host cells, the 
viral genome is reverse transcribed into double stranded DNA (dsDNA). The dsDNA is 
integrated into the host DNA (provirus stage) where the virus uses the host machinery to 
produce billions of virus copies [41, 42].  
1.3.2 Acute (primary) HIV-1 infection      
During the early phase of HIV-1 infection and for the subsequent course of the disease, HIV-1 
preferentially infects activated CD4+ T cells expressing CCR5 [45]. The time interval between 
infection of the first cell and the presence of detectable virus in circulation is called eclipse 
phase [46]. It is difficult to clearly establish the length of the eclipse phase since, for the 
majority of HIV-1 infections, the time of exact exposure is unknown; the eclipse phase is 
however considered to last for approximately 10-14 days. During this phase patients are 
asymptomatic and there is no reliable laboratory test to detect the presence of HIV-1 [47]. A 
study conducted in the SIV infected macaque model demonstrated small numbers of SIV RNA 
copies detected at the site of virus inoculation 3 days after infection; the virus was found in 
different lymphoid tissues and disseminated to other organs at day 12 post-infection [48]. The 
next phase of the infection, also known as acute (primary) HIV-1 infection, has been divided 
into four stages (Fiebig stages I to IV) based on the reactivity of the samples in different assays 
[46]. During acute infection, patients could be asymptomatic or hospitalized due to severe 
illness associated with seroconversion [49]; a viral set-point, which can reach up to 107 or more 
HIV-1 RNA copies/ml, can be detected in peripheral blood during acute infection [50, 51]. At 
this time point, the risk of HIV-1 transmission is higher compared to the chronic phase of 
infection [38]. The virus disseminates to organs and lymphoid tissues, mainly to the gut-
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associated lymphoid tissue (GALT), which is enriched with memory CD4+ T cells [38, 52]. 
HIV-1 causes severe destruction of the gut memory CD4+ T cells and establishes viral 
reservoirs [41].  
During the acute phase of HIV-1 infection, infants may experience cough due to pneumonia, 
diarrhea, fever, lymphadenopathy and skin rash [53, 54]. As MTCT can occur at different time 
points, the course of the disease associated to HIV-1 infection varies depending on the time 
point of the infection [55]. A meta-analysis study reported that the death rate in ART naïve 
children within the first 12 months of life was 52% for children infected during peripartum and 
26% for children infected at postpartum [56]. Higher risk of morbidity and mortality, with an 
increased susceptibility to infectious diseases, was reported for HIV-1 exposed uninfected 
(HEU) infants compared to unexposed infants [57].  
1.3.3 Chronic HIV-1 infection        
The chronic phase of HIV-1 infection starts after a sharp decline of HIV-1 RNA levels at the 
end of acute HIV-1 infection [52]. Reduced HIV-1 viral load could be due to a strong cellular 
immune response in HIV-1 infected individuals [52, 58]. At this stage, HIV-1 infected 
individuals are asymptomatic and can live for a decade or longer in the absence of ART [59, 
60]. HIV-1 viral load remains stable, even below detection limits, in slow progressors, and the 
CD4+ T cells counts decline slowly before AIDS-related complications begin [52, 58]. Early 
initiation of ART significantly changes the course the disease; in fact, in ART treated patients, 
the median life expectancy of 75 years is shortened only by 7 years [61].  
Disease progression in children is more rapid than in adults. For instance, a study conducted in 
Malawi showed that 89% of HIV-1 infected ART naïve children died at the age of 3 years, due 
to a high burden of infectious diseases and lack of appropriate treatment for these 
infections [62]. A study conducted in Rwanda showed that the risk of death in children, who are 
naïve for ART and without prophylaxis for opportunistic infections, was 45% and 62% at the 
age of 2 and 5 years, respectively [63]. A study conducted in three Sub-Saharan countries from 
2004 to 2009 reported a 4.5% death rate for children who were on ART for an average 2.3 years 
[64]. A 6.6% mortality rate was recorded in the Asia region (Thailand, Malaysia, India, 
Indonesia and Cambodia) where 77% of the children were on ART; in this study, however, a 
higher mortality rate was reported during the first months of ART showing the need of early 
diagnosis and effective treatment [65]. In addition, a follow-up study which was conducted in 
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vertically HIV-1 infected children in the US from 1993 to 2006 revealed that the median age of 
death increased from 8.9 in 1994 to 18.2 years in 2006 [66]; a 24.5% death rate was reported in 
children who were not receiving ART [66].  
A mortality rate (16.85 deaths per 1000 child-year) was reported among HIV-1 infected 
children from the northern part of Ethiopia; in this group the early age mortality was higher due 
to lack of timely ART initiation [67]. According to a study conducted in Addis Ababa, 10.4% 
mortality was recorded and the majority of deaths occurred during the first 6 months of ART 
initiation [68]. Successful and early ART treatment normalized the CD4+ and CD8+ T cells 
counts, reduced the viral load to below detectable limit, increased the survival of HIV-1 
infected individuals and decreased HIV-1 transmission [69, 70]. HIV-1 infected children can 
reach adulthood age with proper management of opportunistic infections (OIs); however, early 
initiation of ART and high levels of adherence to treatment is critical [71, 72].  
CD4+ T cells count below 200 μl/ml and/or evidence for at least one AIDS-defining conditions 
are used to diagnose HIV-1 infected patients with AIDS, according to CDC definitions [73]. 
AIDS-defining conditions include mycobacterium infection at any site, recurrent bacterial 
infection, HIV-1 related encephalopathy, wasting syndrome associated with HIV-1 and herpes 
simplex infection [73]. Prior to the introduction of ART in the clinical management of HIV-1 
infection, AIDS diagnosis was associated with fatal outcome within a short period. While ART 
has significantly reduced the burden of AIDS, patients are still suffering from serious non-AIDS 
morbidity and pill burden [74].  
1.3.3.1 HIV-1 Reservoirs  
Even in the absence of detectable HIV-1 RNA during ART treatment, integrated HIV-1 proviral 
DNA persists in tissues [75] and in peripheral blood mononuclear cells (PBMCs) [76]. HIV-1 
predominantly persists in resting central memory (CM) and transitional memory (TM) CD4+ T 
cells due to the fact that these cells can live for an average of 25 years [77-79]. Tissue T 
follicular helper (Tfh) cells, which reside in the lymph node within the germinal center (GC), 
are also major HIV-1 reservoirs [80]. Non CD4+ T cells including follicular dendritic cells 
(FDCs) [81], macrophages (in the lung (alveolar macrophages) [82], liver (Kupffer cells) [83, 
84], bone marrow (osteoclasts) [85] and central nervous system (microglial cells) [86]), 
monocytes [87, 88] and dendritic cells (DCs) [89] are also involved in HIV-1 latency. Thus, any 
approach to reactivate HIV-1 in latently infected cells should consider all possible virus 
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reservoirs in the tissues and peripheral blood for successful functional or sterilizing cure of 
HIV-1 infected individuals [90, 91]. 
Several studies demonstrated that HIV-1 reservoirs in infected individuals persist even after 
protracted ART treatment [92-95]. Early ART initiation in vertically HIV-1 infected children 
induced a size reduction of the virus reservoirs and decay over time [96, 97]. Before initiation of 
ART, adult HIV-1 infected individuals had a similar size of the virus reservoirs in circulation 
during acute and chronic HIV-1 infection; the integrated HIV-1 DNA was significantly reduced 
after 12 months of ART in early treated but not in chronically infected patients [98]. These 
findings suggest that the timing of ART initiation, but not the length of ART, is the most 
important factor to reduce the size of virus reservoirs [99].  
A study was conducted to assess the timing of virus reservoir seeding by infecting rhesus 
monkeys with SIV through the intra-rectal route followed by ART initiation at 3, 7, 10 and 14 
days from virus inoculation. Rhesus monkeys treated with ART at day 3 from mucosal SIV 
infection showed undetectable viral RNA, and undetectable humoral and cellular responses to 
SIV proteins using Enzyme-linked immunosorbent assay (ELISA) and Enzyme-linked 
immunospot assay (ELISpot), respectively [100]. Integrated SIV DNA was also undetectable in 
PBMCs; low, detectable levels of proviral DNA were however measured in lymph nodes and 
gastrointestinal mucosa mononuclear cells, suggesting that SIV seeding may have occurred 
during the primary infection phase before detection of SIV RNA in the circulation [100].  
A child denominated the ‘Mississippi baby’ had been on ART for 18 months immediately after 
birth with treatment discontinued for the following 27 months; the child had undetectable viral 
HIV-1 DNA and RNA copies up to 30 months of age suggesting that very early ART initiation 
may impact on the establishment of latency [101]. Regrettably, an HIV-1 rebound was detected 
in plasma during a routine follow-up at the age of 46.4 months in the absence of any apparent 
clinical symptoms of acute HIV-1 syndrome. The viral load dropped, the frequency of CD4+ T 
cells increased and the CD4/CD8 T cell ratio normalized within 72 hours from ART re-
introduction [102]. Another case report showed that in a child who was on ART from 30 min 
following birth, HIV-1 serological tests were negative and HIV-1 RNA and DNA levels 
undetectable. In this child, ART treatment was interrupted at 48 months of age but, unlike the 
‘Mississippi baby’, the virus rebounded quickly within days from treatment interruption; HIV-1 
RNA declined to undetectable limits after ART was re-initiated at 6 weeks from treatment 
interruption [103]. Among 100 perinatally infected children, only one child treated with ART at 
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the age of 3 months, with treatment discontinued between 5.8 to 6.8 years of age, showed a 
stable CD4+ T cell count, very low levels of circulating HIV-1 RNA and DNA for the 
following 11.5 years [104]. As limited and conflictual results have been shown on 
elimination/reduction of virus reservoirs upon prolonged treatment, ART interruption should be 
handled with caution; in addition, an increased risk of immunosuppression after re-initiation of 
ART has been reported [97, 101, 105]. 
1.3.3.2 Measuring the size of virus reservoirs   
Quantitative virus outgrowth assay (VOA) is the golden-standard method for measuring the size 
of HIV-1 reservoir in resting CD4+ T cells. The assay measures the production of viral protein 
or RNA using ELISA or PCR after co-culture of resting CD4+ T cells with irradiated allogeneic 
PBMCs in the presence of phytohemagglutinin (PHA) [106, 107]. This process is time-
consuming, labor intensive, expensive and needs a large volume of blood.  Furthermore, VOA 
only measures the replication-competent virus but not the defective or non-induced proviruses; 
in fact VOA measured 100 fold less virus reservoirs compared to PCR based assays [108]. PCR 
based assays have been used to measure all types of proviruses including replication-competent 
and defective proviruses from PBMCs, total CD4+ or resting CD4+ T cells [109]. Initiation of 
ART during acute HIV-1 infection may lead to accumulation of defective virus over time which 
will only be detected using PCR based assays [108]. There is an urgent need of developing a 
simple, reproducible and accurate assay which measures the true size of virus reservoir from 
acute and chronic HIV-1 infected individuals (figure 2).   
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Figure 2. Vann diagram comparison of proviral HIV-1 DNA measured by different (existing 
and needed) methods for assessing latent reservoirs (Adapted from [109]). 
1.3.3.3 Microbial translocation and immune activation during HIV-1 infection 
Microbial products translocated from the intestinal lumen to the circulation as result of the 
damage taking place at the epithelial barrier, are associated with immune activation and co-
morbidity in HIV-1 infection [110, 111]. Peptidoglycan, lipopolysaccharide (LPS), lipoteichoic 
acid, flagellin, bacterial DNA/RNA fragments, LPS-binding protein (LBP) and soluble CD14 
(sCD14) are some of the biomarkers used to measure microbial translocation in HIV-1 infected 
and healthy individuals [112, 113]. LBP is an acute phase protein produced by hepatocytes and 
sCD14 is produced by monocytes in response to LPS. Both LBP and sCD14 are indirect 
biomarkers produced by innate immune cells during microbial translocation; they bind to- and 
present LPS [114]. The concentration of LPS significantly increases over the course of HIV-1 
infection although the levels of LPS are similar between chronically infected and AIDS 
patients. Antibiotic treated rhesus macaques showed a marked reduction of LPS levels and 
gram-negative bacteria in the stool demonstrating the involvement of the gastrointestinal tract in 
microbial translocation [110].  
Several studies pointed out that microbial translocation directly or indirectly increased 
polyclonal T cell activation through chemokines and cytokines [110, 115, 116]. Chronic HIV-1 
infected individuals receiving ART showed a significantly different fecal microbial composition 
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compared to healthy controls, and plasma levels of LPS positively correlated with plasma 
immune activation markers including IL-6, TNF-?, C-reactive protein (CRP) and IL-1? [117]. 
SIV infected macaques treated with sevelamer, a drug which block LPS in the intestine, showed 
reduced levels of immune activation markers as measured by a lower frequency of Ki67+CD4+ 
and HLA-DR+CD38+ CD8+ T cells compared to untreated macaques [111]. A study conducted 
in HIV-1 infected humans confirmed that plasma LPS directly correlated with immune 
activation markers such as plasma IFN-α and frequency of HLA-DR+CD38+ CD8+ T cells; 
plasma LPS levels were reduced when the CD4+ T cells count increased upon ART [110]. A 
study conducted in ART-naïve children also showed that microbial translocation could more 
often be measured in severely immunocompromised children [115]. Plasma levels of LPS and 
16S rDNA were significantly elevated in HIV-1 infected children compared to healthy controls; 
they were also positively correlated with HIV-1 RNA, expression of immune activation (HLA-
DR and CD38) and immune exhaustion (PD1) markers on T cells [115]. Thus, treatment 
targeting intestinal bacteria may help to reduce polyclonal immune activation and disease 
progression.   
1.3.4 Antiretroviral therapy (ART) for HIV-1 infection 
One of the great achievements in the field of HIV-1 research is the design of antiretroviral 
drugs. The availability and use of ART improves the quality of life of infected individuals, 
reduces HIV-1 related morbidity and mortality, and changes the natural history of the disease 
into a chronic manageable condition. Recommendations for timing of ART initiation have been 
updated at several occasions by WHO, in order to optimally treat HIV-1 infected individuals 
and to prevent HIV-1 transmission between individuals [118, 119]. Previously the 
recommendations for ART initiation were based on age, CD4+ T cells count or CD4%, clinical 
stages, pregnancy status and co-infection(s) of HIV-1 infected individuals [120]. ART treatment 
interruption was suggested to alleviate pill burden, fatigue, drug toxicity and resistance in    
HIV-1 infected individuals who had been on ART for a longer time [121, 122]. However, upon 
treatment interruption, virus rebound took place immediately from long-lived latently infected 
cells and treatment interruption is not currently considered as an option in the clinical 
management of HIV-1 infection [123, 124]. 
The Food and Drug Administration (FDA) has approved more than 25 drugs with six distinct 
mechanisms of action for the treatment of HIV infection; nucleoside/nucleotide reverse 
transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), 
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protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), CCR5 antagonists and 
fusion inhibitors [125]. The choice of which type of ART should be administered depends on 
the patient characteristics (age, weight), drug resistance profiles, availability of the drugs, 
possible side effects, co-infections and possible drug interactions [126]. Standard ART regimen 
consists of the combination of at least three drugs to suppress HIV-1 replication and reduce the 
risk of drug resistance development; the combinations are two NRTIs with one NNRTIs, or PI 
or INSTI. Clinical evaluations, CD4+ T cells count and HIV-1 viral load are the most common 
tools to monitor the patient response to ART, drug toxicities, treatment adherence and disease 
progression. The time interval for monitoring patients on ART depends on the type of drug 
regimen, the patient age and clinical status; it is however common that clinical monitoring takes 
place every three to six months [126]. A recent guideline recommended the provision of 
lifelong ART to all HIV-1 infected individuals regardless of their CD4+ T cell count; this 
strategy would led to declined levels of viremia in treated individuals and help with the goal of 
ending AIDS epidemic by 2030 [119].   
1.3.5 Adherence to ART  
Adherence to ART is a complex behavior which can be influenced by the type of drugs, life 
style and age of the patients, stage of the disease and the health care system in the country of 
residence [127]. The adherence rate is low in children compared to adults because children are 
dependent on their parents or caregivers for monthly checkup and drug refill. Therefore, 
children adherence will be good only when their caregiver handle the medication properly [127-
131]. A meta-analysis study in children and young adolescents showed that in Africa the overall 
ART adherence was 83.8% varying between 63% in Uganda to 95% in South Africa; the lowest 
rate (53%) was reported from North America [132]. A study conducted in five health facilities 
in Rwanda showed that ART adherence was 66% in children less than 15 years of age; HIV-1 
positive caregivers facilitated for a higher adherence rate compared to HIV-1 negative [128]. In 
three regions of Ethiopia, the adherence rate was estimated to be between 84-95% using a 
caregiver-questionnaire report in the past 7 days prior to interviews [129, 133, 134]. However, a 
very low adherence was also reported using home-based pill counts which, compared to the 
caregiver-report, displayed the need for urgent intervention to improve ART adherence in 
Ethiopia [129].  
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1.4 HEPATITIS B VIRUS (HBV)  
The HBV is an enveloped and partially dsDNA virus classified under the hepadnaviridae 
family. The virion is composed of an inner nucleocapsid core antigen (HBcAg) and an outer 
lipid bilayer envelope that contains the surface antigen (HBsAg) [135]. HBV causes a life-
treating infection; the long-term complications of HBV infection are severe, including hepatic 
failure secondary to liver cirrhosis and hepatocellular carcinoma (HCC) [136]. The burden of 
chronic HBV is due to infection occurring during childhood with clinical complications 
typically affecting the adult individual [137]. While the HBV vaccine was shown to be highly 
protective in HIV-1 seronegative individuals, HIV-1 infected children showed less optimal and 
durable serological responses (Table 1) [138].  
1.4.1 HBV epidemiology  
The majority of HBV infections occur through perinatal and other transmission routes including 
sexual contact (common transmission), needles used in common drug-injection, tattooing, 
unsafe medical practices and contaminated blood or blood products [139]. Around 2 billion 
people have serological evidence of past or current HBV infection [136]; 257 million people are 
chronically infected with HBV based on positive HBsAg results and 887 thousand deaths were 
recorded due to HBV infection related complications in 2015 [140]. According to a WHO 
report, the prevalence of HBV infection varied markedly throughout different world regions 
[140]. The virus is highly endemic, with 70–95% serological evidence of past or present HBV 
infection, in developing regions such as South East Asia, China, sub-Saharan Africa and the 
Amazon Basin. In these areas, at least 8% of individuals in the population are chronic HBV 
carriers [141]. HIV-1 and HBV shared similar routes of transmission, thus among the 36.7 
million people living globally with HIV-1 infection, 5-10% are co-infected with HBV [142].   
Sweden is a low endemic country for HBV infection as the rate of HBsAg positivity was below 
1% and less than 5% for overall markers including HBsAg, Hepatitis B core antibody (anti-
HBc) and anti-Hbs [143]. In Ethiopia, the prevalence of HBV infection varies across regions; a 
meta-analysis showed that the pooled prevalence of HBsAg positivity was 7.4% [144]. A study 
conducted in 57 thousand blood donors from all regions of Ethiopia showed that the overall 
prevalence of HBV infection was 3.9% in adults; the rate of infection was twice higher in the 
male compared to female population [145]. HBsAg prevalence was 7% in the capital city, 
Addis Ababa, as reported from a community-based study [146]. HIV-1/HBV co-infection was 
5.5% for outpatient ART treated individuals at the Gondar Hospital [147]. A similar result was 
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reported from the Mekelle Hospital in northern Ethiopia with 5.9% HBsAg positivity among 
HIV-1 infected adults receiving ART [148]. 
Four major HBV serotypes (adr, adw, ayr, ayw) and nine sub-serotypes (ayw1, ayw2, ayw3, 
ayw4, ayr, adw2, adw4, adrq+ and adrq-) have been identified based on the HBsAg. These 
classifications were based on the constant “a” determinant, two mutually exclusive determinants 
(w/r and d/y) and additional variables. According to the HBV genome sequence, ten genotypes 
(A-J) have been characterized and further sub-genotypes also introduced. Genotypes and sub-
genotypes classifications were based on intergroup nucleotide differences of the complete HBV 
genome sequence > 8% and 4-8%, respectively [149-151]. Genotypes A and D are more 
dominant in Africa and Europe; sub-genotype A1 is common in sub-Saharan Africa and A2 in 
Northern Europe [150, 151]. In Sweden, the genotype D was dominant in patients who visited 
outpatient clinics, followed by A, C, E and F; the different genotypes illustrated the origin of the 
patients as genotypes D, A and C were isolated from few Swedish born patients [152]. A study 
conducted on 391 HBsAg positive samples donated for blood transfusion purpose in five 
regions of Ethiopia showed that genotype A was predominant, followed by genotype D. The 
sub-genotype A1 and four D sub-genotypes, D1, D2, D4 and D6, were also reported [153]. 
HBV serotypes showed that adw2 was the leading serotype, followed by ayw2 and ayw3 [154]. 
Genotypes are linked with clinical and treatment outcomes: for instance genotype A and B 
showed a better HBsAg clearance; genotypes C, D and G showed a poor response to IFN-? 
treatment and genotypes C, D and F had a more significant association with HCC as compared 
with other genotypes [151].   
1.4.2 Pathogenesis of HBV infection 
Initial HBV infection could be symptomatic or asymptomatic; most infections are self-limiting 
in immunocompetent adults, but 5% of these individuals will develop persistent or chronic 
HBV infection. The proportion of chronic infections varies with the age of infection; 80-90% of 
infants are infected vertically at birth or horizontally during the first year of their life and 30-
50% of children infected before the age of 6 years develop chronic HBV infection [140]. 
Cellular and humoral immune responses are responsible for successful clearance of HBV 
infection, although the detailed clearance mechanism is yet not well defined [155]. The virus is 
non-cytopathic; however, liver injury and related clinical manifestations are triggered by 
immune-mediated responses of the hosts [156]. HBV infection of hepatocytes is mediated by 
the interaction of sodium taurocholate co-transporting polypeptide (NTCP) and the pre-S1 
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region of the HBV surface protein [157]. Upon entry of the virus into the host cell, the partially 
double stranded (relaxed circular) viral DNA is repaired to form a covalently closed circular 
DNA (cccDNA) which will be integrated into the hepatocyte genome (Figure 3). Viral cccDNA 
serves as template to form pre-genomic ribonucleic acid (pgRNA) and all viral transcripts; the 
virus uses its own reverse transcriptase to form the HBV DNA genome from pgRNA. Another 
key feature of cccDNA is its ability to persist in the host and to resist current anti-HBV 
treatments [156, 158, 159]. 
 
Figure 3. Schematic representation of the HBV life cycle in human hepatocytes. The steps 
shown in the figure are: HBV virus entry into an hepatocyte, uncoating of the virus particle, 
transport of the nucleocapsid to the nucleus, repair of relaxed circular DNA to form cccDNA, 
integration, transcription, translation, encapsidation, reverse transcription, partially circular + 
DNA formation, assembly and release [156, 158-160]. cccDNA: covalently closed circular 
DNA; pgRNA: pre-genomic RNA; Ags: antigens (HBsAg and HBeAg). 
The average incubation time of hepatitis B virus is 75 days but may vary between 30-180 days 
[140]. The HBsAg and IgM antibodies against the HBV core (anti-HBc IgM) are detected in the 
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blood of HBV infected individuals [161]. The presence of hepatitis B e antigen (HBeAg) 
indicates virus replication and infectivity; transition from the presence of HBeAg to anti-HBe 
seroconversion reflects the transition from active phase to inactive phase of infection [162]. In 
the chronic phase of infection, 6 months after initial encounter with the virus, the HBsAg can be 
detected although the HBeAg may not be in circulation [140]. The outcome of HBV chronic 
infection varies between patients, with the majority being asymptomatic without any liver 
damage [163]. Co-infections with other viruses [HIV, Hepatitis C virus (HCV), Hepatitis D 
virus (HDV)], age, family history and alcoholism are some of the risk factors which contribute 
to the progression of chronic HBV infection to fibrosis, cirrhosis or HCC [164].  
Toll-like receptors (TLRs) ensure a first line of defence against viral infection.Upon injection of 
TLR ligands into mice activation of TLRs takes place with induction of cytokines which inhibit 
HBV replication; accordingly, activation of TLRs may be a future treatment strategy for chronic 
HBV infection [165]. Interferon (IFN)-????produced by DCs, and IFN-??released from Natural 
Killer (NK) cells, NK T cells and Kupffer cells and interleukins (IL-12 and IL-18) are important 
for viral control without damaging hepatocytes [163, 166]. B and T (CD4+ and CD8+) cells 
play a pivotal role in the control of HBV infection and determine its outcome as illustrated in 
Figure 4 [167]. Cytotoxic CD8+ T cells are critical for rapid clearance of virus harbouring cells 
during acute HBV infection. As a proof of this, HBV DNA was at its pick when chimpanzees 
were treated with an anti-CD8 antibody; the re-appearance of CD8+ T cells led to a decline in 
viremia and reduced risk of disease progression [168]. HBV infected individuals who mounted 
a high HBV-specific CD8+ T cell response during acute infection showed a decline in HBV 
DNA and HBeAg levels, and liver function assays returned to normal levels [169]. The 
frequency of HBV-specific CD8+ T cells was reduced after recovery from acute HBV 
infection; however, the limited number of HBV-specific CD8+ T cells observed in patients at 
the chronic phase of the disease [170] strengthen the role of CD8+ T cells in viral clearance. On 
the other hand, CD8+ T cells can cause liver damage in the process of clearing the virus and T 
cell responses are exhausted in the chronic phase of HBV infection [163]. These exhausted 
CD8+ T cells have impaired cytokines’ production and express multiple inhibitory receptors 
including programmed cell death-1 (PD1) and cytotoxic T lymphocyte-associated antigen-4 
(CTLA-4) [171].   
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Figure 4.  Schematic presentation of immune responses to HBV infection of human hepatocytes. 
Components of the innate immunity, including NKT cells and macrophages, recognize infected 
cells and induce cytokines which will control HBV replication without damaging the 
hepatocytes. Antigen presenting cells (APCs) capture, process and present HBV peptides in the 
context of MHC-I to CD8+ T cells or MHC-II to CD4+  T cells. Activated HBV specific CD8+ 
T cells interact with infected cells and directly kill them through release of perforin and 
granzymes or antiviral cytokines like IFN-? and TNF [156, 158-160, 167]. IFN-???interferon-
gamma; APCs: antigen presenting cells; MØ: macrophage. 
1.4.3 HIV-1 and HBV co-infection  
HIV-1 and HBV share the same route of transmission and a higher prevalence of HBsAg or 
anti-HBc can be detected in co-infected than mono-infected individuals [172]. Both viruses 
aggravate the negative effects of the infections and are known to cause chronic illness, cancer 
and death [3]. HBV vaccine response was low in HIV-1 infected individuals and the chance of 
reverse-seroconversion was also high in these vaccinated, HIV-1 infected people [173]. CD8+ 
T cells are both responsible for virus clearance and pathogenesis in HBV infection; however, as 
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impaired CD8+ T cells were reported during HIV-1 infection the likelihood of clearing acute 
HBV infection is very low in HIV-1 infected people [168, 174]. Co-infected individuals showed 
elevated levels of HBV DNA and HBeAg, and the risk of developing chronic HBV was six-fold 
higher as compared to the mono-infected counterpart [3, 172, 173]. The progression rate to 
cirrhosis and/or HCC is much faster, and liver related mortality is more common, in co-infected 
individuals [175].   
1.4.4 Treatment of HBV infection 
The goal of HBV treatment is to reduce morbidity and mortality related to liver diseases by 
suppressing HBV DNA, improving liver histology and normalizing liver enzymes [176]. A 
complete cure means eradication of cccDNA from all infected hepatocytes without reactivation 
when the patient is off-treatment; nevertheless, there is a gap in chronic HBV infection cure 
strategy due to persistence of cccDNA in the hepatocytes [176, 177]. The most common drugs 
for the treatment of chronic HBV infection are IFN and direct-acting antiviral agents (DAAs); 
DAAs are easy to administer and have less side effects compared to IFN [176]. DAAs act on 
DNA polymerase (reverse transcriptase) which inhibits HBV DNA synthesis. Meanwhile, 
entecavir and tenofovir are the most efficient nucleos(t)ides analogs (NUCs) for the treatment of 
chronic HBV infection [178]. IFN induces the release of intracellular enzymes which degrade 
viral messenger RNA and inhibit protein synthesis; pegylated IFN-?-2a and 2b are common for 
the treatment of chronic hepatitis B [178, 179]. According to the American association for the 
study of liver diseases, pegylated IFN-?2a (for treatment of adults) and IFN-?2b (for children), 
lamivudine, telbivudine, entecavir, adefovir and tenofovir are approved antiviral agents for the 
treatment of chronic HBV [176]. For HIV-1/HBV co-infection, tenofovir, entecavir, lamivudine 
and telbivudine should be considered in the treatment regimen [176]. 
1.5 HEPATITIS B VACCINE  
The use of hepatitis B vaccine has been promoted since the 1980s, based upon reliable results 
from clinical trials. The vaccine has been available since 1982, with 95% efficacy in preventing 
HBV infection and its chronic consequences, and it is the first vaccine against a major human 
cancer [180, 181]. The vaccine is an inactivated product; it is recommended to vaccinate all 
individuals negative for HBV markers, regardless of their HIV-1 status. In 1991, the WHO 
recommended to integrate HBV vaccination into all national immunization programs and by the 
end of 2010, 179 countries had introduced HBV vaccine into their routine vaccination 
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programs. In Africa, the childhood vaccine coverage is about 75% [181] and Ethiopia 
introduced HBV vaccine in 2007 with an initial coverage rate of 73%. In 2016, the Ethiopian 
HBV vaccination coverage rate had increased of 23% compared to 2007, based on childhood 
immunization official report [182].   
1.5.1 HBV vaccine composition  
The HBV vaccines are composed of highly purified HBsAg, a glycoprotein of the outer HBV 
envelope. The first licensed vaccine consisted of HBsAg particles purified from the plasma of 
chronic HBV infected individuals. With the advent of recombinant DNA technology the 
HBsAg gene was inserted into plasmids. The recombinant HBV vaccine is produced using 
yeast and mammalian cells; an adjuvant (aluminum phosphate or aluminum hydroxide) is added 
with thiomersal as preservative. Several yeast species have been used for the expression of 
plasmids, namely Saccharomyces cerevisiae, Pichia pastoris and Hansenula polymorpha. Both 
plasma-derived and recombinant DNA vaccines are safe and elicited protective antibodies after 
three or four series of vaccine doses. HBV vaccine can be available in a monovalent or in a 
combination form mainly with hepatitis A or with other antigens as pentavalent vaccine 
(diphtheria, acellular or whole cell pertussis, tetanus and Haemophilus influenzae type b) [183-
185]. 
1.5.2 Schedules and dosage of HBV vaccine  
Antibody levels against HBsAg ≥ 10 IU/L after vaccination are considered protective against 
HBV infection [186, 187]. A standard HBV vaccination schedule comprising three doses of 
intramuscular or intradermal injection at 0-1-6 months is most common world-wide [188-192]. 
However, in HBV hyperendemic countries and in high risk individuals such as injection drug 
users, prisoners, homeless, travelers and immunocompromised people an accelerated HBV 
vaccination schedule is recommended since it prevents horizontal infection and increases the 
vaccine compliance and coverage [193]. The other advantage of accelerated schedule is the 
ability to elicit higher levels of anti-HBs compared to a standard vaccination schedule [194, 
195]. The schedules for accelerated HBV vaccination can be 0-1-2 months or super rapid 0-7-
21 days; a fourth dose was also recommended at 12 months to slow down the rapid decline of 
anti-HBs antibodies [194]. However, a similar HBV vaccine response rate was achieved in 
standard and accelerated HBV vaccinations [196-198]. 
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The recommended dosage for HBV vaccination is 10 mcg (children) and 20 mcg (adults); 
increasing the dosage might induce better response in HIV-1 infected patients and individuals in 
hemodialysis. To prevent repeated exposure to HBV, intramuscular administration of 40 mcg 
HBV vaccine in deltoid muscle increased vaccine response and protection levels in 
hemodialysis patients [199]. In a study conducted to address HBV vaccine response among 
non-responders HIV-1 infected patients, a high-dose (40 mcg) revaccination was administered 
and the response rate was 66.7% [200].   
1.5.3 Longevity of HBV vaccine responses 
Protection following HBV vaccination is measured using plasma anti-HBs levels which last up 
to 22 years after completing full vaccination doses [201, 202]. It was shown that the levels of 
anti-HBs decline over the years; however, the anamnestic anti-HBs antibody response protected 
the individual from infection upon exposure to HBV during transfusion [203]. Revaccinating 
individuals who lost protective HBV antibodies after receiving HBV vaccination at birth has 
proven this concept; upon booster with a single dose of HBV vaccine a rapid increase in the 
levels of anti-HBs antibody occurred indicating a persistence of a long-term immune memory to 
HBV. This process (anamnestic response) is defined as at least a 4-fold increase in anti-HBs 
antibody concentration after 1 month post-challenge [191, 201, 204-209]. Booster doses should 
be considered for higher risk and immunocompromised individuals.   
1.5.4 HBV vaccine response in HIV-1 infected individuals  
The rate of HBV vaccine response is variable among HIV-1 infected individuals; however, poor 
responses, a rapid decline in anti-HBs levels after a few years from vaccination and/or 
unresponsiveness to the vaccine are the major issues in this group of patients [194]. Numerous 
factors have been associated with impaired vaccine response in HIV-1 infection; low CD4+ T 
cells and high HIV-1 viral loads are some of the main reasons [210]. Moreover, HEU infants 
also show defective humoral and cellular immune responses to infection and childhood 
vaccinations [211-213]. A study conducted in Latin America and the Caribbean showed that 
perinatally HIV-1 infected children had very low (21%) anti-HBs levels after four years from 
HBV vaccination compared to HEU (38%) children. Vaccine response was associated with the 
timing of ART initiation, maintenance of the memory B cell response, but was not linked with 
CD4+ T cells count and viral load [214]. A better vaccine response was recorded from HIV-1 
infected children with CD4+ T cells count higher than 350 cells/?l and viral load below 40 
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RNA copies/ml [215]. In Thailand, HIV-1 infected children who had anti-HBs below protective 
levels were revaccinated at 0, 2 and 6 months; 92% of the HIV-1 infected children responded to 
the HBV vaccine and the main reasons for this high HBV vaccine response rate were successful 
treatment with ART for 31 months before vaccination and HIV-1 RNA copies below detection 
limits at the time of vaccination [216]. In Cameron, HEU and healthy controls had a similar 
HBV vaccine response rate; the levels of anti-HBs were however significantly different 
between the groups with 37% of HIV-1 exposed (infected and uninfected) and 61% of healthy 
controls displaying anti-HBs above 10 IU/L (protective-response) [217]. Moreover, 43% of 
HIV-1 exposed exhibited low levels (1-9 IU/L) of anti-HBs compared to 21% healthy controls.  
On the other hand, HIV-1 infected children displayed either an insufficient (56%) or a 
protective (20%) response [217]. The longevity of anti-HBs in HIV-1 infected children varies 
with the time of sampling from the last vaccination; at 5.7 years only 24% of children 
maintained protective anti-HBs [218] and at 9.6 years 1% [219]. Table 1 summarizes the HBV 
vaccine response among children and adolescents (HEU, HIV-1 infected and healthy controls) 
in different parts of the world.  
Ray and colleagues showed that doubling the HBV vaccine dosage improved the response rate 
of non-responder HIV-1 infected participants [220]. Another study conducted in HIV-1 infected 
adults reported a higher HBV vaccine response in double dose recipients as compared to 
standard dose [221]. A meta-analysis study revealed a different response rate in double dose 
HBV vaccine recipients with non-responders showing an excellent response to double vaccine 
dose [9]. Intradermal vaccination in celiac patients elicited higher anti-HBs compared to the 
intramuscular route [222]. Similarly, HIV-1 infected individuals exhibited a better response to 
intradermal vaccination compared to standard dose intramuscular injection [223]. In summary, 
regular monitoring and booster doses may slow down the rapidly declining anti-HBs levels in 
HIV-1 infected individuals.  
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Table 1: HBV vaccine response in HIV-1 infected, HIV-1-exposed uninfected and healthy control children from different parts of the world  
References Country  HBV Vaccine response rate ART status Age 
[214] Latin America 20.9% HIV-1 infected and 37.8% HEU 60.2%  0-11 months HEU, 5-51 
months HIV-1 infected 
[224] Morocco 76% HC and 29% HIV-1 infected  71.4%  10 months to 10 years  
[225] South Africa  61.1% HC and 15.8 HIV-1 infected All  5 - 15 years 
[217] Cameroon 60.71% HC, 51.72% HEU and  
20% HIV-1 infected 
All  6-47 months 
[226] India  94% HIV-1 infected (DD)  81.8%  Under 15 years 
[6] Italy 30.8% HIV-1 infected 94.8%  6-28 years 
[227] The Netherlands  97% HIV-1 infected 89%  1-16 years  
[215] Rwanda 71% HIV-1 infected All  9.3-14.2 years 
[228] Tanzania  59.5% HIV-1 infected 52.8%  1-10 years 
[219] Thailand 1% HIV-1 infected All  7.1-12.1 years 
[229] Tanzania  74.3% HC and 25.7% HIV-1 infected None  2-59 months  
HC: healthy controls; HEU: HIV-1-exposed uninfected; DD: double dose
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1.6 T AND B LYMPHOCYTES IN VACCINE RESPONSES 
Most vaccines induce strong, potent and long lasting immune responses which will enable the 
host to neutralize pathogens and control the pathogenesis of infectious diseases. Protein 
vaccines, including HBV vaccine, elicit strong T-cell dependent responses after administration 
into the skin. APCs (DCs, monocytes, macrophages) capture and process the antigens [230, 
231]; they migrate from the skin to draining lymph nodes through lymphatic vessels where they 
can present peptides in the context of the major MHC complex to T cells [230]. For the 
generation of long-lasting memory to vaccines, migration of T and B cells to the secondary 
lymphoid tissues and interaction of these cells in the GC is critical. B and T cells interaction in 
the GC generates memory B lymphocytes, which contribute to the rapid and effective response 
occurring upon antigen re-exposure, and long lived plasma cells, which ensures the 
maintenance of protecting levels of vaccine specific antibodies for many years [232, 233].  
Naïve T lymphocytes, both with CD4 helper function and CD8 cytotoxic function, express a T 
cell receptor (TCR) and co-receptors which recognize cognate antigen peptides presented either 
within the major MHC-II molecule on the surface of APCs for CD4+ T cells or MHC-I on any 
nucleated cells for CD8+ T cells [234]. T helper (Th) cells can be divided into Th1, Th2, Th17, 
Th9, Tfh and T regulatory (Treg) based on the expression of the different cytokines which they 
produce. The differentiation of specific types of T cells are regulated through transcription 
factors and cytokines present at the immunological synapsis [235, 236]. Each subtype is 
governed by the following cytokines: Th1 by IL-12, Th2 by IL-4, Th17 by transforming growth 
factor (TGF)-β, IL-1β, IL-6, IL-21 and IL-23, Th9 by TGF-β + IL-4, Tfh by IL-21, IL-12, IL-23 
together with TGF-β and Treg by TGF-β. Specific subsets of T helper cells are known to have 
master transcriptional regulators: T-box transcription factor (T-bet) for Th1, GATA-binding 
protein 3 (GATA-3) for Th2, retinoic acid receptor-related orphan receptor-γt (RORγt) for 
Th17, Interferon-regulatory factor 4 (IRF-4) and PU.1 for Th9, B cell lymphoma 6 (Bcl6) for 
Tfh and forkhead box P3 (FOXP3) for Treg cells [236-240].  
CD4+ T cells expressing C-X-C chemokine receptor type 5 (CXCR5) provide help to B cells in 
the lymphoid follicles to differentiate into plasma cells and memory B cells [241, 242]. The 
expression of CXCR5 promotes the migration of cells towards chemokine C-X-C ligand 13 
(CXCL13) in the B cell follicles and down-regulates the expression of the C-C chemokine 
receptor type 7 (CCR7) to facilitate localization in the follicles [241, 242]. Memory CD4+ T 
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cells, sorted by CXCR5 expression, upon stimulation with anti-CD3 expressed lower levels of 
IL-10, IFN-γ and IL-4 compared to Treg, Th1 and Th2 cells, respectively. This finding 
suggested that CXCR5+ cells are a distinct population of T cells; this concept was also 
strengthened by the observation that CXCR5+ T cells, when co-cultured with B cells, induced a 
15 fold increase in IgM production compared to CXCR5- T cells [241]. Tonsillar CXCR5+ T 
cells are activated cells with effector function; peripheral CXCR5+ T cells, however, are in a 
resting state and have a weak migration capacity [241, 242]. In 2009, Bcl6, the lineage defining 
transcription factor for Tfh cells, was discovered as Bcl6 deficient mice showed a defect in Tfh 
cells development and impaired GC reactions [243-245].   
B-lymphocytes are the central element for humoral immunity and are responsible for antibody 
production in response to pathogens and vaccinations. After development in the bone marrow, 
mature naïve B-cells re-circulate to secondary lymphoid organs and, in response to antigen 
activation, they differentiate into memory B cells and plasma cells [232]. Activated B cells 
migrate to the T-B cells border to receive co-stimulatory signal from CD4+ T cells; the fate of 
activated B cells can either be to differentiate into antibody-producing cells through an extra-
follicular pathway or migrate to GC [246]. Antibodies generated through the extra-follicular 
pathway are important for rapid protection and the main pathway of antibody production 
against polysaccharide bacterial capsules or polysaccharide vaccines [247, 248]. GC B cells 
upregulate Bcl6 which controls GC reaction and regulates survival of B cells [249]. The 
expression of CXCR4 by GC B cells maintains their localization in the dark zone where their 
ligand CXCL12 is highly expressed; stromal cells are the main source of CXCL12 [250]. In the 
final phases of proliferation and somatic hypermutation (SHM) in the dark zone, GC B cells 
upregulate CXCR5 and migrate from the dark zone into the light zone where there is a higher 
CXCL13 concentration [250]. In addition to antibody production, B cells are efficient antigen 
presenters and can stimulate CD4+ T cells. They also produce cytokines such as IL-2, IL-6, IL-
10, IFN-γ and TNF-α which play a vital role in controlling allergies, autoimmunity, 
malignancies and infections [251, 252].   
1.6.1 Differentiation and maturation of Tfh cells 
Differentiation of Tfh cells is a multi-stage process initiated by the cognate interaction of DCs, 
antigen presenter, with naïve CD4 T cells in the secondary lymphoid tissues; this process takes 
place in the T cell zone. A basic helix–loop–helix (bHLH) transcription factor called achaete-
scute homologue 2 (Ascl2) is necessary for the initial stage of development of pre-Tfh cells. A 
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study conducted in mice showed that the expression of Ascl2 leads to upregulation of CXCR5 
and down-regulation of CCR7 expression; these events initiate the migration of naïve T cells 
from the T cell zone to the B cell follicle [253].  
Following the initial step of CD4+ T cell commitment into the Tfh cell lineage mediated by 
Ascl2, the upregulation of the Bcl6 transcription factor is associated with further differentiation 
of Tfh cells which includes high CXCR5 expression. The cytokines produced by DCs, 
including IL-12 and IL-23, are a driving force for Bcl6 expression and Tfh cells’ development 
in humans [254]. In vitro experiments showed that stimulation of human CD4+ T cells with 
anti-CD3 and anti-CD28 promotes CXCR5 and Bcl6 expressions in presence of cytokines. Bcl6 
expression is time dependent and a higher Bcl6 induction was found when IL-12 plus TGF-β, or 
IL-23 plus TGF-β are provided in culture when compared to IL-12 alone. The expression of 
Bcl6 is further enhanced by the addition of IL-1β and IL-6 also produced by DCs [240]. 
Immunization of Bcl6 knockout mice with keyhole limpet hemocyanin (KLH) protein did not 
result in the upregulation of expression of CXCR5 on T cells and GC B cells; however, they 
expressed elevated levels of Th1 (IFN-?), Th2 (IL-4) and Th17 (IL-17) cytokines. Likewise, in 
Bcl6 knockout mice, the expression of genes responsible for Tfh cells development was highly 
diminished but the Th1, Th2 and Th17 related genes were elevated [244]. T cells of Bcl6 
deficient mice differentiate into other lineages and develop spontaneous Th2 inflammation 
which leads to myocarditis and pulmonary vasculitis; elevated IL-4 and IL-17 expression levels 
were measured in T cells of these mice [255-257].  
Bcl6 gene upregulation represses the expression of transcription factors for other subsets of T 
helper cells in a DNA binding dependent manner [244]. Binding of Bcl6 to the promoters of 
transcription factors important for development of Th1 and Th17 cells suppressed the 
production of IFN-γ and IL-17 cytokines, respectively [245]. Bcl6 is also important to induce 
Treg cells in the follicles, known as T follicular regulatory (Tfr) cells, which maintain 
homeostasis of immune cells in the GCs. In the absence of Bcl6, the frequency of Tfr cells is 
reduced and the localization of cells in the GC affected, whereas the distribution of Th1, Th2 
and Th17 was not changed [258]. Thus, Bcl6 expression is vital for Tfr cells function and Tfr 
cells control inflammation mediated by Th2 cells.  
Ascl2, Bcl6 and CXCR5 upregulation is sufficient for the development of pre-Tfh cells and 
migration of Tfh cells to the T–B cell border for cognate interaction with B cells. However, 
additional factors are required for Tfh cell survival and to complete their differentiation. 
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Inducible costimulator (ICOS) is a member of the CD28 family which is expressed on Tfh cells 
and controls the migration of pre-Tfh cells into the B cell follicle. This effect of ICOS is 
dependent on the binding of ICOS ligand (ICOSL) expressed on follicular B cells which do not 
carry antigens. Tfh cells and GC development is impaired in the absence of ICOS ligation with 
ICOSL. ICOS deficient mice cannot upregulate CXCR5 expression on CD4+ T cells and, 
accordingly, the migration of these cells into the B cells zone is impaired. ICOS expression is 
therefore important for the establishment and maintenance of the Tfh cells phenotype; in the 
absence of ICOS, the Tfh cell phenotype is reverted [259, 260].  
1.6.2 B cells maturation  
Humoral immune responses can be T cell independent (towards polysaccharide antigens) or T 
cells dependent (towards protein antigens). Polysaccharide (PS) vaccines induce a poor immune 
response and lack efficacy compared to protein vaccines [261]. Marginal zone (MZ) B cells and 
IgM antibodies are critical for T cell independent responses; there is no SHM due to lack of GC 
formation upon exposure to, or vaccination with, polysaccharide antigens. MZ B cells carry 
poly-reactive B- cell receptors (BCRs) and they act like innate immunity components against 
encapsulated bacteria [262, 263]. Because of their intense and rapid response to capsular 
antigens, MZ B cells are a bridge between early innate and adaptive immunity. MZ B cells 
generate short-lived and low-affinity plasma cells through the extra-follicular pathway without 
inducing memory B cells [264, 265]. Conjugation of polysaccharide antigens with protein 
converts T cell independent (TI) to T cell dependent (TD) responses; the pneumococcal 
polysaccharide-protein conjugate vaccine (PCV) is the best example in this context [261, 266].  
T cells provide help to B cells to generate high-affinity memory B cells and long-lived plasma 
cells; these events require the formation of the special GC microenvironment [246, 248]. B cells 
development is initiated in the secondary lymphoid tissue where they recognize unprocessed or 
processed antigens with their BCRs [267]. Activated B cells express co-stimulatory molecules, 
upregulate CCR7 and present antigen within the MHC-II for cognate interaction with T helper 
cells at the T-B cells border; this process helps B cells to undergo proliferation and 
differentiation into GC B cells [268, 269]. Migration of B cells and interaction with T cells in 
the GC is a bi-directional activation signals which helps differentiation and affinity maturation 
of B cells [248, 269].  
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1.6.3 Germinal center formation  
GCs are transient micro-environments of secondary lymphoid tissues where B cells undergo 
SHM which leads to differentiation into memory B cells and the production of high-affinity 
antibodies [246]. Germ-free animals are devoid of GCs since this structure is formed only 
following response to antigens. When mature B cells meet cognate antigens, after infection or 
immunization, they become activated and upregulate the expression of CXCR5 [270]. GC B 
cells proliferate in the dark zone of the follicle; proliferation facilitates the mutation of antibody 
variable region of the antigen binding segments. During this process, the size of the GC 
increases due to the continuous proliferation of B cells which are now defined as centroblasts. 
Centroblasts migrate to the light zone to become centrocytes; this step needs interaction of 
centrocytes with FDCs and Tfh cells. In the sparsely populated light zone, B cells interact with 
FDCs and Tfh cells. Centrocytes with higher affinity receive survival signals; cells with low 
affinity migrate back to the dark zone for further SHM where they rearrange their antigen 
binding sites or die by apoptosis. Centrocytes differentiate into long-lived plasma cells or 
memory B cells which ensure a rapid antibody response during secondary antigen exposure 
[246, 248].  
The interaction between Tfh and B cells is governed by costimulatory molecules and cytokines 
(Figure 5); these include ICOS−ICOSL, CD28−B7, CD40L−CD40, Signaling Lymphocytic 
activation molecule (SLAM)-associated protein (SAP)−CD84, PD1−PDL1, IL-21−IL-21R and 
IL-4−IL-4R [271-276]. Impaired GC reaction and formation were observed in the absence of 
these signaling pathways. ICOS and CD28 are related co-stimulatory molecules which 
modulate Tfh cells proliferation and differentiation [272, 274, 275, 277]. Patients with ICOS 
deficiency present with a severely reduced frequency of peripheral (p)Tfh cells suggesting a 
critical role for ICOS in differentiation of Tfh cells [278]. CD28 is important for differentiation 
and maintenance of Tfh cells as shown by the finding that mice lacking CD28 expression show 
a limited Tfh cells differentiation and present with a reduced ICOS expression [279]. CD40L 
(CD154) is necessary for the maintenance of GC and memory B cells generation [272]; patients 
with deficiency in CD40L expression showed lack of GC formation and a reduced frequency of 
pTfh cells, as also found in ICOS deficient patients [278]. SAP knockout mice had profound 
defects in GC formation and maintenance of Tfh cell differentiation; defective IL-4 and IL-21 
was also observed in these mice [280, 281]. PD1 is an inhibitory molecule which is elevated 
during viral infection; absence of PD1 expression leads to the defective generation of long-lived 
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plasma cells and reduced IL4 and IL21 expressing genes [282]. Tfh cells produce IL-4 and IL-
21 and regulate GC responses [283].     
 
Figure 5. Germinal center (GC) reaction and GC B cell differentiation to memory B and 
plasma cells. B cells can differentiate to plasma cells extra-follicularly, or migrate to the dark 
zone of the GC where they proliferate and undergo somatic hypermutation (SHM) which 
rearranges the variable regions of the antigen binding sites. Thereafter B cells migrate to the 
light zone of the follicle where they interact with Tfh cells and FDCs to receive survival signals 
and differentiate into memory B cells and antibody-producing cells. Tfr cells are important to 
control Tfh cells and GC formation; they also control the development of autoimmunity [247, 
273, 284, 285]. Ab: antibody; Ag: antigen; DZ: dark zone; LZ: light zone; TCR: T cell 
receptor; BCR: B cell receptor; DC: Dendritic cell; FDC: follicular dendritic cell; Tfh cells: T 
follicular helper cell; Tfr cell: T follicular regulatory cell; GC B cell: germinal center B cell; 
IL: interleukin.  
The GC reaction is controlled by special cells called Tfr cells, subset of regulatory T cells [286]. 
Tfr cells (CD4+CXCR5highPD1highFoxp3+) share the characteristics of both Tfh and Treg cells. 
Tfr cells express both Blimp-1 and Bcl6; Blimp-1 is known to down regulate transcription 
factors of Tfh cells [287]. Tfr cells differentiate and proliferate in response to immunization or 
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infection to regulate the size of GC and the magnitude of antibody response [287, 288]. Mice 
deficient in Tfr cells showed a higher magnitude of GC reaction and increased antibody 
production; adoptive transfer of Tfr cells limited GC reactions and the serum antibody levels 
[288, 289]. A study conducted in mice elucidated [290] that Tfr cells regulated Tfh cells 
through PD1/PDL1 signaling; PD1 deficient mice had a higher frequency of Tfr cells. In vitro 
co-culture of B and Tfh cells in presence of Tfr cells showed a significant suppression of IgG 
production due to attenuation of responder cells [290].  
1.6.4 The role of Tfh and B cells in vaccine response  
Vaccines are the best measure to protect people from communicable diseases. Childhood 
vaccines provide protection by eliciting antibodies which can neutralize pathogens. Current 
available vaccines save billions of life; however, we still need to improve the existing vaccines 
and search for new vaccines for deadly pathogens including HIV-1, Hepatitis C virus, Zika 
virus, Plasmodium falciparum and Mycobacterium tuberculosis. The response to vaccines 
varies with the immunological status, gender, age and genetic background of the individual, in 
addition to underlying diseases and type and manufacturing of vaccines [291]. 
Improving GCs reaction will help GC B cells to undergo extensive proliferation and increase 
the antibody diversity through SHM. A study done to assess the role of IL-7 treatment in 
influenza vaccine response found that the frequency of vaccine specific Tfh cells was enhanced 
upon co-delivery of the vaccine with IL-7 fused to the mouse Fc portion (IL-7-mFc); there was 
no effect of this compound on other subsets of T cells. The enhanced frequency of Tfh cells 
increased the frequency of GC B cells, as compared with vaccine delivery alone. Blocking IL-7 
alone, or in combination with Tfh differentiation cytokines IL-6 and IL-21, significantly 
reduced the frequency of Tfh cells. In addition, mice vaccinated after CD4+ T cells depletion 
were unable to generate IgG responses in presence of IL-7, illustrating the crucial role of CD4+ 
T cells for differentiation of Tfh cells, GC formation and for eliciting high IgG production 
[292]. A study conducted to assess the adjuvant effect of IFN-α noted the capacity of IFN-α to 
induce Tfh cells expansion and enhance GCs formation [293].  
Several studies showed that memory Tfh cells found in blood are representative of the Tfh cells 
found in lymphoid tissue [294, 295]; thus studying pTfh cells represents a possible approach to 
understand the immunology of tissue Tfh cells. The frequency of pTfh cells is associated with 
vaccine response and, interestingly, an increase in ICOS+PD1+CXCR3+ Tfh cells correlated 
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with antibody avidity after vaccination with influenza trivalent inactivated vaccine [296]. 
Influenza vaccines significantly increased the frequency of circulating plasmablasts 
(CD19+CD20-CD38+ cells) and high antibody levels persisted for 6 months; interestingly, the 
frequency of IL-21+ICOS+ Tfh cells correlated with hemagglutination inhibition (HAI) titers 
[297]. Another study on influenza vaccination also indicated that the frequency of 
ICOS+CXCR3+ Tfh cells correlated with influenza specific antibody responses [298]. A 
clinical trial for a new vaccine to control Ebola virus outbreak analyzed the immune responses 
to a recombinant vaccine candidate (rVSV-ZEBOV); it was shown that the frequency of Tfh 
cells increased after 28 days of vaccination and Th17-like Tfh cells significantly increased after 
vaccination compared to Th1- or Th2-like Tfh cells [299].  
The plasma CXCL13 reflects GC activities and correlates with generation of specific antibodies 
[300]. This finding could be of help to monitor vaccine responses in lymphoid tissue of humans 
which are otherwise inaccessible for large clinical studies. However, higher CXCL13 plasma 
levels are reported in various pathological conditions of humans including immune 
thrombocytopenia [301], Systemic lupus erythematosus (SLE) [302], rheumatoid arthritis [303], 
idiopathic pulmonary fibrosis [304] and HIV-1 infection [305, 306]. Therefore, antibody titers 
to vaccine currently remain the best validated correlate of protective immunity after vaccination 
[307]. As alluded to above, Tfh cells are important for vaccine response by enhancing GC 
formation and production of high affinity antibodies.  
1.7 VACCINE RESPONSES AND TFH CELLS IN HIV-1 INFECTION 
Responses to immunizations are complex, requiring communication between several immune 
cells which develop during the first year of life [308, 309], a process which may be 
quantitatively and qualitatively affected by HIV-1 infection. Since HIV-1 infection is primarily 
a disease of lymphoid tissues and causes massive destruction of CD4+ T cells, these 
pathological features may not be completely restored by ART [310]. Tfh cells expressed higher 
levels of PD1 in lymph node tissue from HIV-1 infected individuals; elevated cellular PD1 
levels inhibited ICOS expression and the secretion of IL-4 and IL-21 cytokines [311].  
The frequency of blood memory B cells was significantly reduced in HIV-1 infected subjects, 
in both ART-naïve and treated individuals. The decline of memory B cells correlated to 
reduction of antibody titers against measles, tetanus and pneumococcus in HIV-1 infected 
patients compared with healthy controls [312-314]. Timing of ART initiation is the major factor 
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predicting the longevity of B-cell responses to routine childhood vaccines in HIV-1 infected 
children [315]. The results from the latter study showed that initiation of ART in HIV-1 
infected children within the first year of life permits the normal development and maintenance 
of memory B-cells. On the contrary, the frequency of memory B-cells and the level of 
antibodies to a specific vaccine were remarkably reduced in children treated later with ART 
[315]. Experiments conducted in macaques infected with SIV have however indicated that 
depletion of memory B cells from the blood may be due to an increase in homing of these cells 
to lymphoid tissues during the acute phase of infection followed by apoptosis in lymphoid 
tissues, the latter process mediated by death receptors [316]. The presence of HIV-1 infection 
from birth may completely redirect the immunological process aimed at generating high affinity 
antibodies and serological memory.  
In spite of ART, HIV-1 persists in cellular reservoirs which are mostly represented by resting 
central memory T cells [317]; it has yet not been studied whether the size of the HIV-1 reservoir 
has an influence on the response to childhood vaccines in HIV-1 infected children. Other 
pathological mechanisms taking place during HIV-1 infection, including abnormal immune 
activation which persists to some level in spite of ART, may affect response to vaccines in 
children and adults infected with HIV-1.   
1.7.1 Impaired B cell distribution and function during HIV-1 infection 
B cells play a crucial role in mounting humoral immunity during infections or vaccinations. 
They can also efficiently present antigens in the context of MHC-II to CD4+T cells and direct 
the CD4+ T cells response towards Th1/Tfh cells [318]. Functional impairment and alteration in 
the distribution of B cells have been reported during HIV-1 infection [319-322]. Even though 
there is no evidence of direct HIV-1 infection of B cells, the virus can bind to mature B cells 
through complement receptor 2 (CR2) or CD21; this interaction may promote B cell activation 
by the virus and help virus transfer to T cells while B cells travel to the tissue [323]. The defects 
in the frequency and quality of B cells in HIV-1 infection vary with the treatment status, but are 
more pronounced in treatment naïve compared to ART treated patients [321, 324, 325]. A 
higher frequency of immature transitional B cells in circulation was described in HIV-1 infected 
children and adults; these cells have a weak proliferation capacity upon stimulation with anti-
IgM [326-328]. An increase in tissue like- and activated memory B cells, accompanied by a 
decline in naïve and resting memory B cells, are other immunological features of HIV-1 
infected individuals, including perinatally infected children [329]. A reduced frequency of 
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resting memory B cells, regardless of viral load titer, was reported in HIV-1 infected Kenyan 
children; low proportion of pTfh cells were associated with a low proportion of resting memory 
B cells [330]. 
Plasma levels of B cells-activating factor receptor (BAFF), an important molecule for B cell 
maturation and survival, were elevated during acute HIV-1 infection [331, 332] and throughout 
the course of HIV-1 infection [333]. Higher plasma levels of BAFF were also reported in HIV-1 
infected children [334]. However, the expression of BAFF-receptor (R) on B cells was reduced 
in viremic HIV-1 infected individuals thus likely leading to insufficient survival signals 
delivered to B cells [335]. Muema and colleagues reported an increase frequency of B cell 
subsets that expressed low levels of BR3 (also called BAFF-R); elevated plasma BAFF levels 
were associated with BR3 internalization thus probably directly involved in down-regulation of 
BR3 expression [334]. 
In experiments performed to assess the production of immunoglobulins by co-culturing sorted 
pTfh cells and naïve B cells in the presence of staphylococcal enterotoxin B (SEB), the 
production of IgM and IgG was lower in HIV-1 infected patients compared to healthy controls 
[336]. When sorted Tfh cells from lymph nodes were co-cultured with autologous GC B cells in 
the presence of super-antigen, HIV-1 infected cells produced significantly reduced levels of IgG 
compared to cells from controls [311]. Similar results were observed in SIV infected macaques 
when sorted Tfh cells were co-cultured with B cells [311]. Fine needle biopsies of lymph nodes 
revealed that the frequency of GC B cells and plasma cells were significantly higher in ART 
naïve compared to healthy controls [337]. Elevated numbers of plasma cells correlated with 
serum immunoglobulin and contributed to non-specific immune activation [338]. Alterations of 
memory B cell subsets in the lymph nodes were normalized after 72 weeks of ART and the 
aberrant expansion of plasma cells and GC B cells were reduced after treatment [339].  
1.7.2 Tfh and Tfr cells in HIV-1 infection 
Peripheral Tfh cells are affected in frequency and function during HIV-1 infection and this 
impairment is more pronounced in viremic individuals; patients who were successfully treated 
showed similar frequency of pTfh cells as healthy controls. A study conducted in children 
showed that the frequency of pTfh cells (CD4+CD45RO+CXCR5+) was significantly reduced 
in HIV-1 infected individuals compared to healthy controls [329]. The decline in pTfh cells was 
not associated with CD4+ T cells count, viral load, timing of ART initiation and clinical 
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variables. In addition, there was no difference in the frequency of ICOS+ Tfh cells between 
HIV-1 infected and healthy controls [329]. A study conducted with samples collected during 
seasonal flu vaccination showed that the proportion of pTfh (CD4+CD45RO+CCR7+CXCR5+) 
cells was similar in HIV-1 infected children and age matched healthy controls [340]. The genes 
ABCB1, DUSP4, BST2, SAMHD1 and IL21 induced from CD4+ T cells are important for 
pTfh cells proliferations and strongly associated with the production of influenza specific, high 
affinity antibodies in the responder group. However, the study also suggested that CD4+ T cells 
induced genes (FAS, CCR5, LAG3 and IL2) responsible for inhibition of pTfh cells´ 
differentiation prior to influenza vaccination in the non-responder group [340]. A lower 
proportion of pTfh cells was found in ART naïve HIV-1 infected individuals compared to 
healthy controls; the frequency of Tfh normalized after 48 weeks of ART treatment [336]. 
Tfh cells and their expression of co-stimulatory molecules were similar between healthy 
controls, chronic aviremic and elite controllers (ECs). However, aberrant antibody production 
was observed in chronic aviremic individuals compared to HC and ECs after Tfh cells co-
culture with B cells, suggesting a defective T-B cells interaction [341]. Co-culture of pTfh with 
autologous B cells induced higher IL-2 production in chronic aviremic compared to ECs and 
healthy controls. IL-2 signaling was reversed by addition of ?IL-2 antibody in the co-culture 
which inhibited Tbet and Blimp-1 expression in Tfh cells, thus significantly increasing the 
expression of CXCR5 and IgG production [341]. The frequency of pTfh cells (CD4+CXCR5+) 
was similar between ART treated HIV-1 infected adults and healthy controls [342]. After H1N1 
influenza vaccination, co-culture of sorted pTfh cells with autologous B cells supported IgG 
production in HC and HIV-1 infected vaccine responders but not in vaccine non-responders 
[342]. 
Studies showed that abnormal expansion of Tfh cells in the secondary lymphoid organs affected 
the distribution and proliferation of B cells and resulted in defective antibody production. The 
frequency of lymph node Tfh (CD4+CXCR5+PD1+) cells were significantly higher in HIV-1 
infected compared to uninfected controls; this finding was associated with higher expression of 
Bcl6 [343]. HIV-1 specific Tfh cells expressed higher levels of IL-21 in chronic infected 
individuals compared to treated patients [343]. The proportion of splenic Tfh cells was elevated 
in HIV-1 infected individuals and gene expression of signal transducer and activator of 
transcription (STAT)-3, important for full differentiation of Tfh, was reduced in the spleen of 
HIV-1 infected patients compared to healthy controls [344].  
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A study conducted by Colineau and colleagues demonstrated a significantly higher proportion 
of splenic Tfr cells in HIV-1 infected patients and linked the alteration of B cell responses with 
a depressed production of IL-4 and IL-10 by Tfh cells which are necessary for B cells 
maturation [344]. HIV-1 infected individuals had the highest absolute numbers of Tfr cells 
compared to uninfected controls in all section of the lymph nodes, which affected the GC 
reaction and humoral immune responses [345]. A marked increase of Tfh and Tfr cells was 
observed in lymph nodes of chronically SIV infected rhesus macaques compared to acutely 
infected and non-infected animals [346]. The ratio of Tfh cells to Tfr cells was low in chronic 
SIV infection and the frequency of Tfr cells out of Tfh cells was also reduced in SIV infected 
compared to uninfected macaques; this phenomenon may contribute to the increase in the 
frequency of Tfh cells in the chronic phase of the infection [346]. However, a lower frequency 
of Tfr cells was reported in chronic SIV infected macaques and associated with expansion of 
Tfh cell in the lymph nodes [347]. Taking the above points together, defective phenotypes and 
functions of Tfh and Tfr cells during chronic HIV-1 infection were associated with impaired B 
cell frequency and function. 
1.7.3 Tfh cells as HIV-1 reservoirs 
A complete eradication of HIV-1 from the circulation and tissue is still impossible due to the 
persistence of the virus in tissue reservoirs [348, 349]. ART has a low penetration capacity into 
the GCs, as a study showed that intracellular concentrations of ART drugs were low in lymph 
nodes compared to peripheral blood [350]. Moreover, there was a direct correlation between the 
amount of virus bound to FDC and the number of HIV-1 RNA positive CD4+ T cells in the 
tissue, although peripheral blood HIV-1 RNA copies was below the detection limits; these 
findings suggest that there is an ongoing viral replication and production in the tissues during 
ART [350]. Pallikkuth and colleagues performed in vitro activation of sorted pTfh 
(CCR7+CXCR5+) or non-pTfh (CCR7+CXCR5-) cells from healthy donors with 
phytohemagglutinin (PHA) in the presence of green fluorescent protein (GFP) expressing   
HIV-1; pTfh cells were more susceptible to HIV-1 infection compared to non-pTfh cells [80]. 
In cells extracted from the tonsils, GC Tfh cells were more permissive than extra-follicular cells 
for ex vivo infection with GFP expressing HIV-1. Moreover, GC area of the follicles had the 
highest frequency of HIV-1 RNA positive cells compared with the non-GC area in lymph nodes 
collected from ART naïve HIV-1 infected patients without AIDS [351]. Total HIV-1 DNA 
levels were unchanged in pTfh cells after 48 weeks of ART suggesting that pTfh play an 
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important role as virus reservoirs [80]. CCR5-using virus preferentially infected human and 
macaques Tfh cells [352, 353]. In humanized mice, CXCR5+PD1+ Tfh cells exhibited a high 
permissivity to HIV-1 infection and these cells expressed high levels of CCR5 and CXCR3 
[354]. Overexpression of Bcl6 increased the susceptibility of Tfh cells to HIV-1 infection and 
significantly facilitated HIV-1 replication; Bcl6 may thus represent a future target to reduce 
virus reservoirs in the tissues [355].  
The size of virus reservoirs varies with timing of ART initiation; a study conducted by Amu et 
al reported a significantly higher number of HIV-1 DNA copies in PBMCs of late treated 
compared to early treated HIV-1 infected individuals [99]. When the size of virus reservoirs 
was compared between ECs and ART treated HIV-1 infected individuals, a significantly 
elevated number of HIV-1 DNA copies was detected in pTfh cells of ART treated compared to 
ECs suggesting that some unknown mechanism may account for virus clearance in ECs [356]. 
Ultrasound-guided fine needle biopsies collected from inguinal lymph nodes showed that 
frequency of Tfh (PD1+CXCR5+) out of memory CD4+ T cells was higher in ART naïve 
patients compared to healthy controls. The study also confirmed that HIV-1 DNA copies were 
elevated in lymph nodes compared to peripheral blood; this difference was only observed in 
ART naïve but not in treated patients [337]. Samples collected from lymph nodes showed that 
ART naïve individuals had an elevated frequency of Tfh cells compared to healthy controls and 
patients treated with ART for 72 weeks [339]. This study also revealed that Tfh cells 
(CXCR5+PD1+) carried a higher number of HIV-1 DNA copies than CXCR5+PD1- cells and 
that the size of the virus reservoirs was reduced after ART initiation [339]. The expansion of 
Tfh cells correlated significantly with plasma viral load, suggesting a role of Tfh cells in virus 
replication and production [339]. Ex vivo experiments by Miller and colleagues showed that Tfr 
cells were highly permissive for HIV-1 infection compared to Tfh cells when tonsil cells from 
HIV-1 uninfected children were cultured with CCR5-tropic HIV-1 isolates [357]. Thus, early 
initiation of ART reduces the size of virus reservoirs and maintains the integrity of Tfh cells in 
the tissue of HIV-1 infected individuals, which in turn helps GC formation and development 
GC for better immune responses to vaccines.   
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2 CHAPTER II: OBJECTIVES 
The aims of this thesis are:  
? to evaluate the functional and phenotypic properties of Tfh cells in ART treated HIV-1 
infected and healthy control children (paper I)   
? to measure serological and Tfh cell responses to HBV vaccine in HIV-1 infected 
children receiving ART and healthy children with no prior exposure to HBV vaccine or 
infection (paper II)   
? to assess the role of hepatitis B vaccination in reducing the size of HIV-1 reservoirs in 
ART treated children (paper III)   
? to investigate the possible impairment of B cell subsets of HIV-1 infected children in 
relation to HBV vaccine responses (preliminary results)  
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3 CHAPTER III: MATERIALS AND METHODS 
All studies were performed with specimens obtained from HIV-1 infected and healthy control 
children from Addis Ababa, Ethiopia and Stockholm, Sweden. The experiments were approved 
by the AHRI/ALERT Ethical review committee, National Research Ethics Review committee 
of Ethiopia and the Ethical committee of Karolinska Institutet. The study purpose, benefit and 
possible discomforts were clearly explained to the parents and then written informed consent 
was collected. Blood samples were collected by experienced nurses, to minimize the discomfort 
and pain during sample collection.  
Study participants and cohorts  
Study I 
A cross sectional study was conducted between 2013 and 2014; 48 HIV-1 infected and 55 
healthy controls were recruited from All Africa Leprosy, Tuberculosis and Rehabilitation 
Training (ALERT) Center of pediatric ward and Woreda 02/03 clinic, Addis Ababa, Ethiopia. 
Blood samples were collected from children between 2–7 years of age. All HIV-1 infected 
children were on ART and only for 12 children (26.1%) treatment was initiated before 12 
months of age; children received ART for an average period of 37.0 months (range 8–66 
months). Twenty children had HIV-1 RNA copies between 200 and 582000 copies/mL and 
eight of them had a viral load higher than 10000 copies/mL. 
Study II 
This was a prospective cohort study conducted at the Zewditu Memorial Hospital and the 
Pediatric department of ALERT Center in Addis Ababa, Ethiopia. Age matched healthy 
controls were recruited from two childcare centers in Addis Ababa (Muday Charity 
organization and SOS village). HBV vaccine was administrated intramuscularly to a total of 
63 healthy controls and 49 HIV-1 infected children. All HIV-1 infected children were on 
ART for a mean period of 41.8 months. Prior to HBV vaccination, 73.5% (36) of the HIV-1 
infected children had plasma HIV-1 RNA copies below 150 copies/ml and only 18.4% (9) of 
them had over 1000 copies/ml. 
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Study III 
This was a prospective study conducted at Karolinska University Hospital enrolling 22 HIV-1 
infected children (8 males and 14 females) for HAV and HBV vaccination with Twinrix 
(GlaxoSmithKline AB). The median age was 15 years (range 6–18 years). The viral load at 
the time of vaccination was undetectable (<20 copies/mL) and the median CD4+ T cells count 
was 715 cells/μL. All children were on ART and for median length of 7.2 years.  
Preliminary results 
A cross-sectional study was conducted in 54 healthy controls and 53 HIV-1 infected children 
who received hepatitis B vaccination in Ethiopia. The mean age of the healthy controls and 
HIV-1 infected children was similar. The mean CD4+T cell count of HIV-1 infected children at 
the time of sample collection was 942 cells/?l. Fifteen of the HIV-1 infected children were 
naïve for ART and 38 received ART for a mean of 44.6 months. 
Hepatitis vaccination of children (Papers II and III) 
Recombinant DNA (rDNA) Hepatitis B vaccine, which consists of purified HBsAg was 
administered to Ethiopian children (paper II and preliminary results). For the Swedish 
cohort, Twinrix, a combination of vaccines against HAV (inactivated) and HBV 
(recombinant), was administrated intramuscularly (paper III). All children received three 
doses (each of 10 mcg) of vaccine with 4-weeks interval (accelerated vaccination schedule) 
between the doses. There was no severe adverse event reported upon vaccination in both 
study cohorts except that children felt pain at the site of injection.  
Peripheral blood mononuclear cells (PBMCs) isolation (all papers) 
Blood samples were collected at baseline (prior to vaccination) and at 1 and 6 months from 
the last dose of vaccine (papers II, preliminary results and paper III); only one sample was 
collected at one time point for paper I. After the plasma fraction was collected from the 
samples, whole blood was diluted with RPMI-1640 and layered in Falcon™ 15 mL 
Polypropylene conical Tubes which were filled with 3 ml Ficoll-Paque. PBMCs were isolated 
by standard Ficoll-Paque density gradient centrifugation. PBMCs were then cryopreserved in 
liquid nitrogen (-160°C) until needed. In paper I, additional 400 ?l of whole blood were 
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transferred to standard flow cytometry staining tubes and lysed with red blood cells lysing 
solution prior to B cell immunostainings.  
Plasma HIV-1 viral load determination (All papers and preliminary results) 
RNA was extracted from plasma and HIV-1 RNA levels were measured using Quantitative 
Real-Time HIV-1 assay. 
Measurement of total PBMC HIV-1 DNA (paper III) 
DNA was extracted from PBMC manually with High Pure Viral Nucleic Acid Kit. Light 
Cycler 96 system (Roche) was used to measure total HIV-1 DNA copies in PBMCs.  
Determination of plasma anti-HBs, anti-HAV and CXCL13 titers (paper II, III and 
preliminary result) 
Anti-HBs Monolisa Plus assay (paper II, preliminary results and paper III) and Human 
CXCL13 DuoSet ELISA (paper II) were used to measure the plasma levels of anti-HBs and 
CXCL13 chemokine, respectively. Total (IgG and IgM) HAV antibodies, and IgM on a 
separate test, were measured by electro-chemiluminescence immunoassay (paper III). The 
assays were run according to the instruction provided by the manufacturers and all samples 
and standards were tested in duplicate. 
PBMCs stimulation (paper I and II) 
PBMCs were stimulated with PMA (phorbol 12-myristate-13-acetate) and Ionomycin in the 
presence of Golgistop (paper I). In paper II, PBMCs were cultured with BD FastImmune 
CD28/CD49d costimulatory complex alone or together with the HBsAg protein. At day 5, 
Golgistop was added to all culture conditions to block release of cytokines from cells.  
Flow cytometry (all papers and preliminary results) 
Cells and appropriate antibodies to cell surface molecules were added to standard flow 
cytometry staining tubes. For intracellular staining, surface stained cells were permeabilized 
using BD Cytofix/Cytoperm and stained with monoclonal antibodies. Cells were fixed in 2% 
paraformaldehyde and the samples acquired in LSR-II flow cytometer. 
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4 CHAPTER VI: RESULTS AND DISCUSSION 
4.1 PAPER I: IMPAIRED PHENOTYPE AND FUNCTION OF PTFH CELLS IN 
HIV-1 INFECTED CHILDREN RECEIVING ART 
Tfh cells are critical for GC formation and differentiation of GC B cells to long-lived plasma 
cells and memory B cells. Peripheral Tfh (pTfh) cells are the counterparts of tissue Tfh cells 
[294, 295]. We characterized pTfh based on the expression of CXCR5 among memory CD4+ T 
cells [278]. We also used the expression of CCR6 and CXCR3 chemokine receptors to identify 
Th1, Th2 and Th17-like Tfh cells [358]. Besides, the expressions of ICOS and PD1 were 
assessed on pTfh cells [359]. The aim of this study was to elucidate the distribution of pTfh 
cells and B cell subsets in HIV-1 infected children receiving ART. 
Our finding disclosed a significantly reduced frequency of pTfh cells in HIV-1 infected 
compared to healthy control children (Figure 6a) in spite of the fact that the frequency of 
CD4+CD45RO+ memory T cells was significantly higher in HIV-1 infected children. There 
was no difference in pTfh cells’ frequency between aviremic and viremic HIV-1 infected 
children (Figure 6a). Co-stimulatory molecules are critical for the interaction between Tfh and 
GC B cells and, accordingly, we measured the expression of ICOS and PD1 on pTfh cells. A 
lower frequency of pTfh cells expressing PD1, ICOS and PD1+ICOS was identified in samples 
from HIV-1 infected children (Figure 6b-d).  
 
Figure 6: Frequencies of pTfh cells (a) and PD1+, ICOS+ and PD1+ ICOS+ pTfh cells (b-d) 
in HIV-1 infected and healthy controls (gated on CD4+CD45RO+ cells). (Contr: controls; 
HIV+: ART treated HIV-1 infected; avir: aviremic; vir: viremic). 
Subsequently, we measured the expression of cytokines IFN-?, IL-2, IL-4 and IL-21 in pTfh 
cells upon in vitro polyclonal stimulation with PMA and ionomycin in the presence of 
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Golgistop. A similar frequency of pTfh cells expressing IFN-?? IL-2 and IL-21 were measured 
in HIV-1 infected children and healthy controls (Figure 7a, b and d); however, a reduced 
frequency of IL-4+ pTfh cells was observed in HIV-1 infected children (Figure 7c). IL-4 is 
critical for B cells survival and differentiation to antibody producing cells in response to 
antigens or vaccines; our finding thus suggests that, in view of the low frequency of IL-4+ 
pTfh cells, vaccine specific responses may be affected in HIV-1 infected children.  
Figure 7: Expression of cytokines (IFN-???IL-2, IL-4 and IL-21) in pTfh cells in heathy controls 
and ART treated HIV-1 infected children; pTfh cells were gated from CD4+CD45RO+ T cells. 
(Contr: controls; HIV+: ART treated HIV-1 infected; avir: aviremic; vir: viremic). 
In addition, B cell subsets were characterized in HIV-1 infected and controls children (Figure 
8); the frequency of CD19+ B cells was reduced in HIV-1 infected children with a lower 
frequency observed in viremic as compared to aviremic children. The frequency of naïve B 
cells (CD19+CD10–CD21+CD27–) was similar between HIV-1 infected and controls; 
however, viremic children displayed a lower frequency of naïve B cells compared to aviremic 
and control children. Resting memory B cells (CD19+CD10–CD21+CD27+), critical for 
serological memory to vaccines and infections, were significantly reduced in HIV-1 infected 
children compared to healthy controls, regardless of their viral load status. A similar frequency 
of activated memory B cells (CD19+CD10–CD21–CD27+) was measured between HIV-1 
infected and control children. Tissue-like memory B cells (CD19+CD10–CD21–CD27–) were 
significantly higher in HIV-1 infected compared to control children. Both populations of 
exhausted B cells (activated memory and tissue-like memory B cells) were significantly higher 
in viremic compared to aviremic and controls children (Figure 8). 
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Figure 8. B cell subsets in 45 (26 aviremic and 19 viremic) HIV-1 infected children and 55 
healthy controls. (Contr: controls; HIV+: ART treated HIV-1 infected; avir: aviremic; vir: 
viremic; RM: resting memory; AM: activated memory; TLM: tissue-liked memory B cells; * 
P<0.05; ** P<0.01; ***P<0.001; ****P<0.0001). 
In paper I, we found profound defects in Tfh cells and B cell subsets of HIV-1 infected 
children who were on ART. The main reason for this could be that ART was initiated when a 
profound immunological damage had already taken place in this children starting from birth. 
ART was initiated when the CD4+ T cell counts were below 350 cells/?l (for 3-5 years old) 
or below 200 cells/?l (older than 5 years) and/or when the children reached the WHO clinical 
stages III and IV, according to the Ethiopian pediatric ART guidelines [360]. The death rate 
among HIV-1 infected, ART naïve children can reach up to 52% before celebrating the 
second year of age [361] with respiratory diseases as the major cause of death [362]. Tissue 
Tfh cells were expanded in chronically HIV-1 infected ART naïve adults and significantly 
affected B cells maturation and differentiation in GC [343]. B cell subsets and 
immunoglobulin production is impaired, directly or indirectly, by HIV-1 infection. Looking at 
the clinical records of the HIV-1 infected children enrolled in the study we found that only 
26.1% started ART within 12 months from birth. Early initiation of ART reduces the 
destruction of CD4+ T cells and increases the longevity of memory B cells [315]. Thus, also 
from an immunological perspective, ART initiation should be recommended for all HIV-1 
infected children from birth as found in the latest WHO guidelines [119]. We were also 
concerned about the ART adherence behaviors of HIV-1 infected children since they had very 
high viral load titers in blood at the time of sample collection. For obvious reasons, the 
treatment adherence of HIV-1 infected children is usually affected by their caregivers or 
parents [127-131]. Therefore, the finding of my study suggests that there should be a close 
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clinical follow-up to reduce treatment failure in children was still present with high viral load 
after 6 months of ART.   
4.2 PAPER II: PTFH CELLS AND ANTIBODY RESPONSES TO HBV VACCINE IN 
HIV-1 INFECTED CHILDREN RECEIVING ART 
HBV infection is a serious health problem in developing countries which can cause acute or 
chronic infection, with the latter leading to cirrhosis or HCC. HBV vaccine can prevent the 
infection and related cancer. It was previously reported that the frequency of pTfh cells 
correlated with the levels of antibody responses to influenza vaccination [298, 363] and to an 
Ebola vaccine candidate [299]. Havenar-Daughon and colleagues reported that plasma CXCL13 
might be a useful marker for monitoring GCs activity during vaccination [300]. My study was 
carried out to characterize the contribution and response of pTfh cells during HBV vaccination 
of HIV-1 infected and age matched healthy controls; in addition, we asked the question on 
whether measurement of CXCL13 in serum would be a useful marker to monitor vaccination 
responses.  
In the context of paper II, we recruited ART treated HIV-1 infected children and healthy 
control children who did not previously receive HBV vaccination. After screening for previous 
HBV exposure and current HBV infection, three doses of HBV vaccine (10 mcg/dose) were 
administered to all children following an accelerated vaccination schedule. HBV vaccine 
responses in children were measured at 1 and 6 months from the last vaccination. We measured 
antibody responses to HBV vaccine and CXCL13 levels in plasma. We characterized the 
frequency of pTfh cells prior and post vaccination and measured in vitro cytokines response of 
pTfh cells upon stimulation of PBMCs with HBsAg protein.  
Except for four HIV-1 infected children, all individuals responded to the HBV vaccine and 
mounted variable antibody levels. Ten HIV-1 infected and two healthy controls had low 
antibody levels (1-2 log IU/L) after 1 month from the last vaccination. HIV-1 infected children 
had significantly lower anti-HBs levels at 1 month and 6 months from the last vaccination 
compared to controls (Figure 9a and b). Our result showed that accelerated HBV vaccination 
elicited high levels of anti-HBs in healthy controls and HIV-1 infected children at 1 month 
from vaccination but the levels of HBV antibody dramatically declined at 6 months from the 
last vaccination (Figure 9c). In fact, we found that 12.15% healthy controls and 22.13% HIV-
1 infected children displayed a reduction of median anti-HBs antibody at 6 months compared 
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to 1 month from the last vaccination (Figure 9c). Based on the findings obtained at 6 months 
from vaccination, consideration should be given to implement the schedule of accelerated 
HBV vaccination with a fourth vaccine dose to slow down the rapid decline in the antibody 
levels and to increase the longevity of HBV vaccine response in resource-limited countries. It 
has been recommended by authorities to introduce a fourth HBV vaccine dose at 12 months 
of age in the accelerated vaccination schedule [194]. Yet, most African countries have not 
followed the recommendation due to logistic and vaccine compliance issues.   
Studies have previously shown that HIV-1 RNA copies transiently increased following 
influenza vaccination [364, 365] whereas other publications have not reported any change in 
this context [366, 367]. In our study, there was no significant change in the number of HIV-1 
RNA copies after HBV vaccination (data not shown). 
 
Figure 9. Plasma levels of anti-HBs after 1 and 6 months from the last vaccination in HIV-1 
infected children and healthy controls (HC: healthy controls; HIV+: ART treated HIV-1 
infected; avir: aviremic; vir: viremic; BL: baseline; M1: 1 month after the last vaccination; 
M6: 6 months after the last vaccination). 
The frequency of pTfh cells was similar before and after vaccination in HIV-1 infected subjects 
and healthy controls (Figure 10a). The expression of CXCR3 and CCR6 in pTfh cells gave us 
the opportunity of characterizing Th1, Th2 and Th17-like pTfh cells [358]. In our study, an 
elevated frequency of Th17-like pTfh cells (CXCR3-CCR6+) was observed in HIV-1 infected 
children compared to healthy controls prior to vaccination while no difference was observed 
after 1 month from vaccination. Interestingly, healthy controls exhibited a significant change in 
the frequency of Th17-like pTfh cells at 1 month post-vaccination compared to baseline (Figure 
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10b). As Th17-like pTfh cells engage in immunity against infectious diseases, including HIV-1 
infection, and autoimmune diseases [368, 369], these cells might possibly also be important for 
vaccine induced memory [299]. We have also found an inverse correlation between the CD4+ T 
cell count and the frequency of Th17-like pTfh cells in HIV-1 infected children prior to 
vaccination (Figure 10c) suggesting a possible immunopathological link between disease 
progression and frequency of Th17-like pTfh cells. On the contrary to what we had shown in 
paper I where the frequency of pTfh cells was significantly lower in HIV-1 infected subjects 
compared to controls, in paper II, there was no difference in the frequency pTfh cells 
between HIV-1 infected and healthy controls. Based on WHO recommendations, in 2014 
ART treatment was provided to all children younger than 15 years of age, regardless of their 
CD4+ T cells count and clinical stage [370]. The cohort of HIV-1 infected children in paper 
II was enrolled in 2015 and most of the children were on ART before their CD4+ T cells 
severely declined, thus avoiding the development of HIV-1 related complications and AIDS-
defining illnesses in this group. It is therefore possible that ART normalized the frequency of 
pTfh cells in HIV-1 infected children who were enrolled in paper II.  
 
Figure 10. Frequency of pTfh cells (a), expression of CXCR3 and CCR6 in pTfh cells (b) and 
correlation of Th17-like pTfh cells with CD4+ T cells. (HC: healthy controls; HIV+: ART 
treated HIV-1 infected; BL: baseline; M1: 1 month after the last vaccination).  
We then measured the frequencies of pTfh cells expressing the cytokines IFN-?, IL-2, IL-4 and 
IL-21 after stimulation of PBMCs for 5 days in presence of the CD28/CD49d costimulatory 
complex alone or together with the HBsAg protein. Similar expression levels of cytokines were 
observed between HIV-1 infected and healthy controls at baseline and at 1 month post-
vaccination. The expression of cytokines was significantly increased in both groups at 1 month 
post-vaccination compared to baseline in PBMCs stimulated with HBsAg protein together with 
co-stimulatory molecules but not cultures treated with the co-costimulatory complex alone 
 45 
 
(Figure 11). In paper II, we are able to set-up a new protocol based on our previous polyclonal 
stimulation experiments (paper I) and a study conducted on CD4+ T cell response upon 
HBsAg protein stimulation [371]. In our experiments, it was striking that pTfh cells from HIV-1 
infected and healthy controls expressed similar levels of cytokines pivotal for Tfh cell biology.  
 
Figure 11. Expression of cytokines (IFN-?, IL-2, IL-4 and IL-21) by pTfh cells after PBMCs 
stimulation with HBsAg protein together with co-stimulatory molecules (Ag) or co-
costimulatory molecules alone (Cos) for 5 days. (HC: healthy controls; HIV+: ART treated 
HIV-1 infected; avir: aviremic; vir: viremic; BL: baseline; M1: 1 month after the last 
vaccination) 
The levels of CXCL13 were significantly higher in HIV-1 infected children at all studied time 
points compared to healthy controls. On this aspect, other related studies have shown similar 
result in HIV-1 infected individuals [305, 306, 372, 373]. There was a similar plasma CXCL13 
concentration at different time points within the groups of controls and HIV-1 infected children; 
however, viremic children had higher levels of CXCL13 compared to aviremic at 6 months 
from vaccination (Figure 12). CXCL13 levels were unchanged after vaccination in both HIV-1 
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infected children and healthy controls. Hence, our study does not support the possibility of 
using CXCL13 plasma levels as biomarkers for GC activities [300]; it is however important to 
assess the role of CXCL13 as biomarker of successful vaccination in larger cohorts.  
 
Figure 12. Plasma CXCL13 levels in healthy controls and HIV-1 infected children (viremic and 
aviremic) prior to vaccination and at 1 month and 6 months from last vaccination dose (HC: 
healthy controls; HIV+: ART treated HIV-1 infected children; avir: aviremic; vir: viremic; BL: 
baseline; M1: 1 month after the last vaccination; M6: 6 months after the last vaccination). 
In paper II, the phenotype and function of pTfh cells were similar between HIV-1 infected 
children and age-matched healthy controls. High plasma levels of anti-HBs were elicited with 
accelerated HBV vaccination schedule. We also demonstrated a rapid decline in the levels of 
anti-HBs over time in HIV-1 infected and healthy controls. However, we were unable to 
provide a possible mechanism for the reduced levels of plasma anti-HBs in HIV-1 infected 
children which would be based on frequency and function of pTfh cells. In paper II the 
frequency and properties of B cell subpopulations were not examined; in the following chapters 
summarizing unpublished results I present results correlating HBV antibody response with B 
cell subpopulations.  
4.3 UNPUBLISHED RESULTS: WHY IS THERE A DISCREPANCY BETWEEN 
THE FREQUENCIES OF PTFH CELLS MEASURED IN PAPER I AND PAPER 
II? 
Further analyses were conducted to understand the differences in pTfh cell frequencies in 
papers I and II. In paper II, the frequency of pTfh cells was similar between HIV-1 infected 
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patients and healthy controls; this observation was different from paper I where a reduced 
frequency of pTfh cells was identified in HIV-1 infected children compared to the controls. 
Other studies also showed a similar frequency of pTfh cells in HIV-1 infected individuals and 
controls [340, 374]. One possible explanation for the differences noticed between papers I 
and II could be due to the degree of HIV-1 replication; in fact in paper I the numbers of 
HIV-1 RNA copies in plasma was significantly higher than paper II (Figure 13a). Moreover, 
there was a significant negative association between pTfh cells and HIV-1 RNA copies 
(Figure 13e). Boswell and colleagues showed that the frequency of pTfh cells was greatly 
affected by high HIV-1 RNA copies [336].  
Guidelines for the timing of ART initiation in HIV-1 infected children were changed during the 
study period as discussed in the result section of papers I and paper II. The median length of 
ART treatment in the cohort of HIV-1 infected children included in paper II was 41.8 months. 
In paper I, the median length of ART treatment was 37 months. According to these clinical 
observations showing that the length of ART treatment did not differ between the two groups of 
HIV-1 infected children, it is difficult to envisage that the different frequencies of pTfh cells in 
the two studies should be related to parameters of ART administration. 
In HIV-1 infected children, the frequency of pTfh cells was higher in paper II compared to 
paper I (Figure 13b). The median age of the children in paper II was significantly higher 
than in paper I both for HIV-1 infected children (Figure 13c) and healthy controls (Figure 
13f). In addition, there was a direct correlation between the frequency of pTfh cells and age in 
HIV-1 infected children (Figure 13d). Thus, age could be another factor for the differences 
noticed in the frequencies of pTfh cells of HIV-1 infected children in the two studies. 
However, similar frequencies of pTfh cells (Figure 13f) were observed in the control groups 
despite an increase in age (Figure 13g) in paper II (S2); there was no correlation between age 
and pTfh cells for controls (Figure 13h).  
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Figure 13. Viral load, frequency of pTfh cells and age in HIV-1 infected children (panels a-e) 
and controls (panels f-h) enrolled in the studies of papers I and II. Study 1 (S1) and study 2 
(S2).  
4.4 PAPER III: HBV VACCINATION IN HIV-1 INFECTED YOUNG ADULTS: A 
TOOL TO REDUCE THE SIZE OF HIV-1 RESERVOIRS?  
The persistence of HIV-1 in resting memory T cells is one of the major obstacles for HIV-1 
eradication. HIV-1 latency is established during the primary phase of the infection and the virus 
persists in long-lived memory T cells. Early initiation of ART reduces the size of the virus 
reservoirs but cannot eliminate the provirus DNA from the host [375]. Several clinical trials 
have been conducted to induce the provirus from the latently infected cells, allowing ART to 
eliminate the induced viruses; this approach is known as “shock and kill” [376].   
We extensively studied pTfh cells in papers I and II, and serological memory to HBV 
vaccination in paper II. We were keen on studying other subsets of CD4+ T cells including 
CD8+ T cells, and the expressions of activation and proliferation markers on these cells in 
relation to hepatitis vaccination and the size of HIV-1 reservoirs measured as total HIV-1 
DNA copies in PBMCs (paper III). A couple of studies showed that CD8+ T cells play a 
critical role in the clearance of HBV during the acute phase of the infection [167, 168]. A recent 
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report showed that HIV-1 specific cytotoxic T lymphocytes were decisive in clearing the virus 
reservoirs in pediatric HIV-1 infection [377]. Thus, we investigated the relation between CD8+ 
T cells and HIV-1 DNA reservoirs in HIV-1 infected children vaccinated for HBV and HAV.  
Twenty-two HIV-1 infected children were recruited to this study (paper III). Protective anti-
HBs (>1 IU/L) were elicited after three doses of accelerated hepatitis vaccination (Figure 14a) 
in all but two children. The size of the virus reservoirs, measured by HIV-1 DNA copies/106 
PBMCs (Figure 14b), was similar prior and post vaccination. However, 54% of the patients 
(Figure 14c) had reduced HIV-1 DNA copies in PBMCs at 1 month from the last vaccination as 
compared to the baseline. We could not confirm that this result was entirely due to the effect of 
hepatitis A and B vaccination as a control group of aged matched HIV-1 infected children not 
receiving vaccination was missing in the study. Previous studies showed that the change in 
HIV-1 DNA copies was 1 log in 1 year and 0.2 log between 1-4 years of ART in HIV-1 
infected children [378]. In a different study, adults showed a fast decay (86%) of HIV-1 DNA 
following 1 year of ART and 23% decay between 1-4 years; the HIV-1 DNA decay reached a 
plateau after 4 years of ART [379]. As the HIV-1 infected children included in paper III had 
been on ART for a median period of 7.2 years, it is likely that a plateau already reached for the 
decline of HIV-1 DNA copies due to ART prior to vaccination conducted in this study. Thus, 
immunological events related to hepatitis vaccination, were likely leading to a change in the 
number of HIV-1 DNA copies.  
 
Figure 14. Plasma levels of anti-HBs (a), HIV-1 DNA copies (b) and difference in HIV-1 DNA 
copies in three groups (c) prior and post vaccination (BL: baseline; M1: 1 month after the last 
vaccination; Decrease: > 10% reduction in HIV-1 DNA copies/106 PBMCs; Stable: < 10% 
increase or decrease in HIV-1 DNA copies; Increase: > 10% increase in HIV-1 DNA copies). 
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Table 2 summarizes the differences in frequency of CD4+ and CD8+ T cell subpopulations and 
expression of activation markers prior and post-vaccination. The frequency of naïve CD4+ T 
cells was reduced following vaccination whereas the frequency of EM CD4+ T cells increased 
at 1 month from vaccination compared to baseline. The frequency of CM CD4+ T cells 
expressing CD38 was significantly reduced at 1 month. CM CD8+T cells increased 
significantly; the frequencies of cells expressing HLA-DR declined among total, CM and EM 
CD8+ T cells. The expression of Ki67 was significantly reduced among CM and EM CD4+ T 
cells and in the total, EM and TEMRA CD8+ T cells at 1 month post-vaccination. Immune 
activation and proliferation is the driving force for disease progression in HIV-1 pathogenesis 
[380]. Our data showed reduced immune activation and proliferation of CD4+ and CD8+ T 
cells post vaccination with Twinrix.  
Table 2. CD4+ and CD8+ T cell subsets and their surface expression of activation and 
proliferation markers in ART treated young children prior and post vaccination.   
T cells 
Difference in CD4+ T cell subsets 
between BL and M1 
Difference in CD8+ T cell subsets 
between BL and M1 
CD4+ CD38 HLA-DR Ki67 CD8+ CD38 HLA-DR Ki67 
Total        * * 
Naïve  **        
CM  **  ** **  *  
EM  *   **     **  ** 
TEMRA        * 
(BL: baseline; M1: 1 month after the last vaccination; CM: central memory; EM: effector 
memory; TEMRA: Terminally differentiated effector memory). 
We further analyzed T cells in patients who had lower HIV-1 DNA copies following 
vaccination and also the two other groups in which HIV-1 DNA was stable or increased; the 
frequency of Ki67+ expressing cells among CM and EM CD4+ T cells (Figure 15a and b) was 
reduced whereas the frequency of CM CD8+ T cells (Figure 15c) was increased at 1 month 
post-vaccination. There was no change in the frequency of CD4+ and CD8+ T cell subsets in 
the stable and increase groups of patients.  
A previous publication reported that HIV-1 infected individuals with low viral load showed low 
levels of immune activation and proliferation of CD4+ T cells [381]. A study conducted to 
predict the half-life of T cells in HIV-1 infected patients showed that CM CD8+ T cells had a 
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shorter half-life (50 days) compared to healthy individuals (100 days). Loss of CM CD8+ T 
cells during HIV-1 infection could be due to a declined expression of IL-7R???a pathogenic 
phenomenon of both CD4 and CD8 T cell which was previously linked to disease progression 
[382, 383]. Thus, reduced proliferation levels of CD4+ T cells and increased CM CD8+ T cells 
in the “decreased” group of HIV-1 infected young adults post-vaccination may be part of the 
mechanism leading to a reduction of HIV-1 DNA copies observed in some children upon 
vaccination with Twinrix.    
 
Figure 15. Frequency of CD4+ and CD8+ T cells and Ki67 expression on subpopulations of 
CD4+ T cells in ‘decrease’, ‘stable’ and ‘increase’ groups of HIV-1 infected young adults prior 
and post HBV vaccination (BL: baseline; M1: 1 month after the last vaccination; Decrease: > 
10% reduction in HIV-1 DNA copies/106 PBMCs; Stable: < 10% increase or decrease in HIV-1 
DNA copies; Increase: > 10% increase in HIV-1 DNA copies). 
Linear regression analysis was performed and a model established to predict the contribution of 
clinical and immunological parameters to the changes of HIV-1 DNA copies between the two 
time points. We first selected parameters which could predict HIV-1 DNA changes by using 
univariate analysis. Next, stepwise multivariate linear regression analysis was used: through 
these calculations we found that 75% of the variance for the decline of HIV-1 DNA after 
vaccination was explained by the frequency of EM CD8+ T cells.  
A role for functional CD8+ T cell responses has been shown for both HBV and HIV-1 
infections. In mice, HBV vaccine elicited a strong and broad CD8+ T cell response which can 
be of use for treatment of chronic HBV infection [384-386]. Moreover, HBV-specific EM 
CD8+ T cells were high in an individual who cleared HBV acute infection [170]. A study 
conducted to assess immune responses upon co-delivery of SIV gag DNA vaccine with IL-12 
showed that EM CD8+ T cells increased significantly in the vaccinated macaques [387]. Viral 
load increased upon depletion of CD8+ T cells with an anti-CD8+ monoclonal antibody 
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suggesting the role of CD8+ T cells in suppressing the virus from circulation [387]. HIV-1 
specific CD8+ T cells reduced the seeding of virus reservoirs in the acute phase of HIV-1 
infection and there was an inverse correlation between HIV-1 DNA copies in PBMCs and 
frequency of effector CD8+ T cells [388]. EM CD8+ T cells were strongly inhibiting SIV 
replication after mucosal challenge of vaccinated macaques [389, 390]. In vitro experiment of 
sorted EM CD8+ T cells co-cultured with HIV-1 infected CD4+ T cells showed a strong and 
consistent inhibition of viral replication from cells obtained from elite controllers [391].  
In summary, HBV vaccination could be a potential candidate strategy to reduce the size of virus 
reservoirs in successfully ART treated patients. This study has the following limitations: the 
number of HIV-1 infected children and young adults in Sweden is very low and finding non- 
HBV vaccinated children was not possible; accordingly we cannot firmly claim that the change 
in HIV-1 DNA copies detected post vaccination was due to vaccination.  
4.5 PRELIMINARY RESULTS: B CELL SUBSETS OF HIV-1 INFECTED 
CHILDREN.  
There was an open question in paper II that should be addressed to explain the differences in 
the anti-HBs levels in healthy controls and HIV-1 infected children. B cells are important 
components in the successful response to vaccines. In this section of preliminary results, I 
explored the possibility that impairments in frequencies of B cell subsets could account for the 
poor serological response to HBV vaccine in HIV-1 infected children reported in paper II.  
The results from these analyses presented in Figure 16 are in line with several previous studies 
which reported a dramatic alteration in B cell subsets of HIV-1 infected children [315, 330, 334, 
392, 393]. A significantly reduced frequency of Naïve, RM and switched B cells (Figure 16C, 
16D and 16G) was found in HIV-1 infected children compared to healthy controls; on the 
contrary, the frequencies of AM and TLM B cells, exhausted B cell subsets, were significantly 
increased in HIV-1 infected children (Figure 16E and F). ART administration contributed to 
restore the frequencies of RM B cells (Figure 16D) and switched B cells (Figure 16G) whereas 
treatment had no impact on the elevated frequencies of AM (Figure 16E) and TLM (Figure 
16F) B cells.   
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Figure 16. Frequency B cell subsets in healthy controls and HIV-1 infected (ART treated and 
naive) children (HC: healthy controls; HIV+: HIV-1 infected; ART: ART treated HIV-1 
infected; Naïve: ART naïve HIV-1 infected; IT: immature transitional B cells; RM: resting 
memory; AM: activated memory; TLM: tissue-liked memory; ns: not significant; * P<0.05; ** 
P<0.01; ***P<0.001; ****P<0.0001). 
We calculated the correlation between the frequencies of B cell subsets and the level of anti-
HBs antibodies and found a significant correlation of anti-HBs antibodies with RM B cells 
(r=0.56; p<0.0001) and switched memory B cells (r=0.35; p=0.02) in HIV-1 infected children 
(Figure 17d and g). There was no correlation between anti-HBs antibody and B cell subsets in 
healthy controls.  
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Figure 17. Correlation between plasma titers of anti-HBs antibody and B cell subsets in HIV-1 
infected children. (IT: immature transitional B cells; RM: resting memory; AM: activated 
memory; TLM: tissue-liked memory; ns: not significant). 
It is evident from these findings that the poor HBV vaccine response observed in paper II was 
mostly likely due to defects existing in the B cell compartment. ART provided to HIV-1 
infected children is critical to improve the distribution and function of B cells. Perturbation of B 
cell subsets, however, can still be found in ART treated children, which may affect vaccine 
specific memory B cells and long-lived plasma cells. 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
Vaccines are the most effective interventions to control infectious diseases and save millions of 
lives globally. More than 250 thousand people are chronic HBV carriers and thousands of lives 
are lost each year globally due to HBV related complications. HBV infection is preventable and 
a vaccine with 95% efficiency is available [140]. A poor response to HBV vaccine was reported 
by several studies in HIV-1 infected individuals and protective HBV antibodies induced by 
vaccination wane faster in HIV-1 infected individuals than in healthy controls.  
Tfh cells and RM B cells are critical components of effective vaccine responses. In paper I, we 
showed that HIV-1 infected children had lower frequencies of pTfh and RM B cells compared 
to healthy controls. As the majority of children included in this study were administered ART 
after one year of age, it is likely that the disruption, or lack of development of immune 
components relevant for response to vaccines occurred in the children before the initiation of 
ART. Thus, early initiation of ART is mandatory to preserve humoral and cellular immune 
responses in children. In paper II, higher plasma levels of anti-HBs were measured in healthy 
controls compared to infected children; antibody responses to the HBV vaccine declined in both 
groups after 6 months. This finding poses a question regarding the timing of accelerated 
vaccination schedule and the importance of adjusting the schedules for HIV-1 infected 
individuals. In addition, the introduction of a fourth dose of HBV vaccine should be assessed in 
the context of resource-limited settings [194]. It would be interesting to further follow the HBV 
vaccine responses in the children enrolled in study II to measure the decay in plasma anti-HBs 
levels after 5 years; these data, together with the ones which we have already collected, could 
be used to calculate the decay of humoral immune responses to HBV vaccine over time using 
mathematical modeling.  
In paper II, we set-up a protocol to measure cytokine expression in pTfh cells upon stimulation 
of PBMCs with the HBsAg protein. In the future, I also would like to perform experiments to 
evaluate the phenotypic and functional characteristics of HBsAg specific CD8+ T cells, a 
parameter that was not evaluated in HIV-1 infected children in our previous studies. To assess 
cytokine expression of HBsAg specific CD8+ T cells may give the opportunity of better 
understanding the role of CD8+ T cells in HBV vaccination; CD8+ T cells are crucial for 
clearance of the virus during acute infection and they are involved in different stages of chronic 
HBV infection [168, 169]. The characteristics of HBsAg specific memory B cells should also 
be studied in this context in healthy and HIV-1 infected children as they play an important role 
in serological memory to HBV vaccine. Based on a recent publication from another group 
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[300], the plasma concentration of CXCL13 was proposed to represent a marker of ongoing GC 
activities. In our study, the plasma concentration of CXCL13 was elevated in HIV-1 infected 
children at all time points and changes in CXCL13 levels were not observed after vaccination in 
either group. Several studies reported that elevated plasma CXCL13 concentration can be found 
during HIV-1 infection, with activated monocytes heavily involved in its production [305, 306, 
372, 373]. Further studies should be conducted to elucidate the use of CXCL13 as a GC activity 
marker and the possibility of using CXCL13 to predict the emergence of cross-neutralizing 
antibodies in HIV-1 infected individuals [331].  
The scale-up of ART in Ethiopia was a timely intervention since early ART initiation mitigates 
immune activation and reduced morbidity and mortality in the patients. A continuous clinical 
follow-up of HIV-1 infected children should be conducted to improve the rate of adherence, to 
monitor treatment failure, to reduce drug related toxicity and ART drug resistance [394]. High 
circulating levels of HIV-1 RNA were detected in some children receiving ART who were 
enrolled in study I and II of this PhD thesis; accordingly, the rate of ART adherence and 
associated factors should be investigated in HIV-1 infected children in ART clinics of Addis 
Ababa and other regions of Ethiopia. 
In Paper III, we showed a possible connection between vaccination against HBV and the 
number of HIV-1 DNA copies in some HIV-1 infected young adults included in a perspective 
vaccination study. There was a similar number of HIV-1 DNA copies pre- and post-vaccination 
in HIV-1 infected young adults included in the study; however, in 54% of these patients there 
was a significant reduction in HIV-1 DNA copies after vaccination. After examining the 
literature in relation to the decay of HIV-1 DNA copies in PBMCs in adults and children 
infected with HIV-1, we concluded that a concrete possibility exists that the change in HIV-1 
DNA copies, representing a measure of HIV-1 reservoir, may be due to HBV vaccination. For a 
better understanding of this observation, I would like to conduct further studies in a large cohort 
of Ethiopian adults by including ART treated patients and healthy controls, previously 
vaccinated or not with HBV vaccines; these cohorts will be useful to assess the effect of ART 
on T cell subsets frequencies and changes in HIV-1 DNA after vaccination.  
Our preliminary results showed that one of the reasons for the low levels of anti-HBs antibody 
in HIV-1 infected children following vaccinations might be the damage occurring to B cell 
subsets, including RM B cells. As previously studied for other childhood vaccines [315], I 
would like to evaluate, in a longitudinal study, the frequency of B cell subsets in HIV-1 infected 
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children treated from birth in Ethiopia and relate the B cell data to childhood vaccine responses. 
These studies could help understanding the dynamics of normalization of B cell subsets as well 
as the longevity of vaccine specific antibody responses in HIV-1 infected children. These 
studies may also be important to support changes in HBV vaccination schedule to improve 
vaccination of HIV-1 infected children.      
In conclusion, we were able to elicit protective anti-HBs antibodies after three doses of HBV 
vaccine using an accelerated vaccine schedule. However, a fast decay of these antibodies was 
noticed in HIV-1 infected children, and to some extent healthy control children, which raises 
the important question on whether these individuals will be protected, in the long run, from 
hepatitis infection and related complications. HIV-1 infected children should be followed 
regularly and booster doses should be administered before the protective HBV antibodies wane 
from circulation.   
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